Document:

Exhibit 10.10

 

CONFIDENTIAL

 

CLINICAL COLLABORATION AGREEMENT

 

This Clinical Collaboration
Agreement (this “Agreement”), made as of August 16, 2018 (the “Effective Date”), is by and
between SpringWorks Subsidiary 3, PBC, a public benefit corporation organized under the laws of Delaware (“SpringWorks”),
and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant
Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 (“BeiGene”).
BeiGene and SpringWorks are each referred to herein as a “Party” and are collectively referred to as the “Parties”.

 

RECITALS

 

WHEREAS, SpringWorks
is developing its proprietary compound designated as PD-0325901 as further described in Part I of Exhibit A (the “SpringWorks
Compound”);

 

WHEREAS, BeiGene is
developing the proprietary compound designated as BGB-283 as further described in Part II of Exhibit A (the “BeiGene
Compound,” with the BeiGene Compound and the SpringWorks Compound referred to generically as a “Compound”);

 

WHEREAS, the Parties
initially desire for BeiGene to conduct a clinical study of the combination of the BeiGene Compound and the SpringWorks Compound,
which study will be a single arm of the clinical trial described on Exhibit B (such combination study, the “Study”);
and

 

WHEREAS, the Parties
will share equally the costs associated with the Study, and BeiGene will supply the BeiGene Compound and SpringWorks will supply
the SpringWorks Compound for purposes of the Study, in accordance with the terms of this Agreement.

 

NOW, THEREFORE, in
consideration of the following mutual promises, covenants and conditions and any sums to be paid, the Parties hereto agree as follows:

 

1.          Governance
and Protocol.

 

(a)          Joint
Steering Committee. The Parties shall form a joint steering committee (the “JSC”), made up of an equal number
(not more than two (2)) of representatives of each of SpringWorks and BeiGene, which shall have responsibility for reviewing and
approving, and coordinating, all activities with respect to the Study, including reviewing and reconciling all Shared Costs and
approving all Budgets. The JSC shall meet as soon as practicable after the Effective Date and then no less than each calendar quarter,
and more often as reasonably considered necessary at the request of either Party. The JSC may meet in person or by means of teleconference,
videoconference or other agreed manner. For those matters identified in this Agreement, or otherwise agreed in writing between
the Parties, to require JSC approval, such approval requires unanimous agreement among all of the members, and the Parties shall
use good faith efforts to reach a unanimous decision as expeditiously as possible; neither Party shall have any tie-breaking vote
but instead will be subject to Article 15. It is understood and agreed that all decisions regarding the Study and Protocol and
performance thereof shall be made by mutual agreement of the Parties acting jointly through the JSC; without limiting the generality
of the foregoing, absent a JSC decision to the contrary and other than for supply of the Compounds, all documents, all third party
contracts, and all regulatory submissions and interactions, in each case pertaining to the Study or Protocol, shall be prepared
jointly by, or engaged in jointly, by the Parties and shall require approval by the JSC.

 

     

     

    

 

(b)          Protocol.
BeiGene shall hold the Investigational New Drug Application (as described in Title 21 of the U.S. Code of Federal Regulations,
Part 312, and the equivalent application in the jurisdictions outside the United States, “IND”) relating to
the Study and shall act as the sponsor of the Study. BeiGene shall not transfer the IND (except in connection with the assignment
of this Agreement pursuant to Section 13) to any Affiliate or third party without SpringWorks prior written consent (which, solely
as necessary for performance of the Study, will not be unreasonably withheld, delayed or conditioned). BeiGene and SpringWorks
shall jointly prepare a protocol for the Study that is consistent with the description on Exhibit B (“Protocol”),
and the final draft of the Protocol shall be submitted to the JSC for its review and approval. Any material changes to the Protocol
will be provided to the JSC 30 days in advance (in electronic form) of submitting such changes to any applicable regulatory agency
or institutional review board (“IRB”), or if not available 30 days in advance, as soon as reasonably available
so that the JSC may approve any such material change, including any cohort expansion or adjustment to dosing regiments. Neither
Party may use or perform the Protocol, or submit the Protocol (or any change thereto), unless previously approved by the JSC. The
Parties acknowledge that the Protocol and all amendments shall be (i) considered the Confidential Information of each Party subject
to Article 7 and (ii) subject to the input of, and amendments by, any applicable regulatory authority or IRB and the terms and
conditions of the clinical trial agreement(s) under which the Study is being performed, all of which under this clause (ii) will
require to be accepted by the JSC to be included as part of the Protocol. No Compound of the other Party, nor any Confidential
Information of the other Party, nor any Study Results or Joint Inventions, in each case shall be used or disclosed by a Party (or
any of their Affiliates or subcontractors, licensees or sublicensees) except for the performance of the Study or as otherwise expressly
permitted hereunder. In the event of a conflict between the Protocol and this Agreement, the terms of this Agreement shall govern,
except in the case of matters related directly to Study procedures themselves, with respect to which the terms of the Protocol
(as approved in accordance with this Section 1(b)) shall govern.

 

2.          Conduct
of the Study; Costs; Fixed Dose Formulation Work.

 

(a)          Conduct
of the Study. BeiGene will perform (or have performed on its behalf through its Affiliate(s) or permitted subcontractor(s))
the Study in accordance with the Protocol and this Agreement; provided, that, the Parties may elect by mutual agreement to have
SpringWorks perform some parts of the Study. Each Party shall comply with all applicable laws, rules and regulations in connection
with the conduct of its obligations under the Protocol and its portion of the Study. Information disclosed to either Party regarding
the Study in meetings or other updates shall be the Confidential Information of each Party subject to Article 7. Each Party will
use commercially reasonable efforts to perform its obligations under the Protocol and its portion of the Study. The Parties acknowledge
that, due to the adaptive design of the Study, Exhibit B and the corresponding Budget may need to be modified to reflect
expansion or extension of the Study (e.g., in success scenarios (to be mutually agreed by the Parties) or due to potential compounding
toxicity resulting in extended dose escalation). In such event, the Parties shall jointly prepare a proposed modification to Exhibit
B and corresponding Budget for submission to the JSC, and the JSC shall promptly meet to review and consider such modifications.

 

     

     

    

 

(b)          Shared
Costs.

 

(i)          Subject
to this Section 2(b), each Party will be solely responsible for its costs associated with manufacturing and supplying its Compound
for the Study. All Shared Costs (as defined below) will be shared equally between the Parties subject to the budgeting process
described below (with the understanding that any other costs accrued by a Party will be the sole responsibility of such Party).

 

(ii)         For
purposes of this Agreement, the following terms shall have the following meanings:

 

“Shared Costs”
means (i) those out-of-pocket costs and expenses paid to any third party in accordance any agreement between a Party and such third
party pursuant to which such third party agrees to conduct a portion of, or provide services with respect to, the Study and solely
to the extent such costs and expenses are approved by the JSC and do not exceed the amounts included in the Budget for that period;
and (ii) the FTE Cost for the number of FTEs actually used in the conduct of the Study in the specified period, solely to the extent
such FTE Cost does not exceed the amount specified in the Budget for that period.

 

“FTE”
means a full-time person, or in the case of less than a full-time person, a full-time equivalent scientific or technical person
year, carried out by an appropriately qualified employee or consultant of a Party or its Affiliates, based on one thousand eight
hundred (1,800) person-hours per year. Overtime, and work on weekends, holidays, and the like will not be counted with any multiplier
(e.g., time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution. Indirect
personnel (including support functions such as managerial, financial, legal, or business development) will not constitute FTEs.
In no event will one person be counted as greater than one (1) FTE.

 

FTE Rate”
means the rate specified on Exhibit C per one (1) full FTE per full twelve (12) month calendar year, [***] ,
including personnel and travel expenses. Starting January 1, 2019, the foregoing rate will adjust on January 1 of each calendar
year by an amount equal to the change, if any, in the Consumer Price Index for All Urban Consumers (CPI-U) for the U.S. City Average,
calculated by the Bureau of Labor Statistics during the immediately preceding calendar year.

 

“FTE Cost”
means, for any period, the FTE Rate multiplied by the number of FTEs used in such period.

 

(iii)        Within
twenty (20) days following the end of each calendar quarter commencing with the first full calendar quarter following the Effective
Date, each Party shall submit to the JSC a written report setting forth in reasonable detail all Shared Costs incurred by each
such Party over such calendar quarter. Within twenty (20) days following the receipt by the JSC of such written reports, the JSC
shall prepare and submit to each Party a written report setting forth in reasonable detail (A) the calculation of all such Shared
Costs incurred by both Parties over such calendar quarter and (B) the calculation of the net amount owed by SpringWorks to BeiGene
or BeiGene to SpringWorks in order to ensure the appropriate sharing of such Shared Costs in accordance with this Section 2(b).
The Party that is due for reimbursement of Shared Costs in the preceding calendar quarter shall invoice the other Party. Such payments
by one Party to reimburse the other Party’s Shared Costs for the purposes of cost sharing under this Agreement shall be paid
within thirty (30) days of receipt of the invoice. In the event that a Party disputes in good faith the amount of the reported
Shared Costs, that Party shall first pay the disputed amount and, subject to the foregoing, submit the disputed matter to the JSC
for resolution.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

(iv)        Subject
to subsection (iii), if any amounts payable by one Party to the other Party under this Agreement are not paid when due, such outstanding
amounts shall accrue interest (from the date such amounts were due through and including the date upon which full payment is made)
at the prime rate as reported by the Wall Street Journal (U.S., Western Edition) on the date such payment is due, plus an additional
1%, or the maximum rate permitted by applicable law, whichever is less.

 

(c)          Budget
and Audit Right. At least ninety (90) days before each January 1 during the Term, the Parties will prepare, and the JSC will
approve, a budget that sets out the estimated aggregate Shared Costs to be incurred, and the estimated quantity of each Compound
required for the succeeding calendar year, on a calendar quarter-by-calendar quarter basis (the “Budget”). The
initial Budget for the Study is attached as Exhibit D. No costs will be shared by the Parties unless included as an estimated
Shared Cost in the applicable Budget, as described above. Either Party shall have the right to request a modification of the Budget
at any time during the Term and the JSC will promptly meet to review and consider such modification. Each Party will keep complete,
true, and accurate books and records in relation to all Shared Costs. Each Party will keep such books and records for at least
three (3) years following the calendar year to which they pertain. Each Party (the “Auditing Party”) may, upon
written request, cause an internationally-recognized independent accounting firm (the “Auditor”) that is reasonably
acceptable to the other Party (the “Audited Party”) to inspect the relevant records of such Audited Party and
its Affiliates to verify the Shared Costs of the Audited Party and the related reports, statements and books of accounts, as applicable.
Before beginning its audit, the Auditor will execute an undertaking acceptable to the Audited Party by which the Auditor agrees
to keep confidential all information reviewed during the audit. Each Party and its Affiliates will make their records available
for inspection by the Auditor during regular business hours at such place or places where such records are customarily kept, upon
receipt of reasonable advance notice from the Auditing Party. The Auditor will review the records solely to verify the accuracy
of the Audited Party’s Shared Costs and its compliance with the financial terms of this Agreement. Such inspection right
will not be exercised more than once in any calendar year and not more frequently than once with respect to records covering any
specific period of time. In addition, the Auditing Party will only be entitled to audit the books and records of the Audited Party
from the three (3) calendar years prior to the calendar year in which the audit request is made. The Auditing Party agrees to hold
in strict confidence all information received and all information learned in the course of any audit or inspection, except to the
extent necessary to enforce its rights under this Agreement or to the extent required to comply with any law, regulation or judicial
order. The Auditor will provide its audit report and basis for any determination to the Audited Party at the time such report is
provided to the Auditing Party before it is considered final. In the event that the final result of the inspection reveals an error
in the amount of Shared Costs reported by the Audited Party, (i) if the effect of the error resulted in an underpayment by the
Auditing Party, the Auditing Party shall promptly pay the Audited Party the underpayment amount and (ii) if the effect of the error
resulted in an overpayment by the Auditing Party, the Audited Party shall promptly pay the Auditing Party the overpayment amount.
The Auditing Party will pay for such inspections, as well as its expenses associated with enforcing its rights with respect to
any payments hereunder. In addition, if the audit discloses an error by the Audited Party of at least [***] of the aggregate amount
of the Shared Costs in any calendar year subject to that audit, then the fees and expenses charged by the Auditor will be paid
by the Audited Party.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

(d)          BeiGene
Compound Supply for Fixed Dose Formulation Work. During the Term, BeiGene will supply to SpringWorks the quantities of BeiGene
Compound specified on Exhibit E for use in the conduct of fixed-dose combination activities to be performed by or on behalf
of SpringWorks in connection with the Study (such activities, the “Fixed Dose Formulation Work”). All BeiGene
Compound supplied by BeiGene under this Section 2(d) shall (i) meet the specifications set forth on Exhibit E, and otherwise
comply with those provisions of Section 6 applicable thereto, including, Sections 6(c), (d), (e) and (f) applied mutatis mutandis,
and (ii) be supplied at BeiGene’s cost and expense other than the Purchased BeiGene Compound (as defined in Exhibit E)
which shall be supplied at the corresponding Transfer Price as set forth in Exhibit E. SpringWorks shall only use such BeiGene
Compound for the conduct of the Fixed Dose Formulation Work.

 

(e)          Exclusivity.

 

(i)          During
the Exclusivity Term (as defined below), (A) SpringWorks and its Affiliates shall not (either alone, or in collaboration or by
subcontract, license or sublicense with any others), clinically develop or commercialize the BeiGene Compound (in any form), except
as expressly permitted by this Agreement or another written agreement between the Parties and (B) BeiGene and its Affiliates shall
not (either alone, or in collaboration or by subcontract, license or sublicense with any others) clinically develop or commercialize
the SpringWorks Compound (in any form), except as expressly permitted by this Agreement or another written agreement between the
Parties. For purposes of this Agreement, “Exclusivity Term” means the longer of (i) [***] from the Effective
Date or (ii) [***] after the end of the Term. This Section 2(e) shall survive any termination (for any reason) or expiration of
this Agreement.

 

(ii)         Without
limiting Section 2(e)(i) above, during the period commencing on the Effective Date and continuing until the earlier of (A) [***]
after the date of [***] and (B) [***], neither Party nor its Affiliates shall (either alone, or in collaboration or by subcontract,
license or sublicense with any others), clinically develop (or prepare to clinically develop) or commercialize the combination
of any selective [***] in any form, or any products comprising, incorporating or containing any such combination, except as expressly
permitted by this Agreement or another written agreement between the Parties.

 

3.          Expansion.
In the event that the Parties reasonably agree that the Study achieved the expansion criteria set forth in Exhibit F, the
Parties will negotiate in good faith for a period of up to [***] a definitive agreement to provide for an expansion of the clinical
collaboration and commercial relationship between the Parties based on the following principles: (a) [***], (b) [***], (c) decisions
on [***] will be made on a joint basis, (d) the exclusivity between the Parties contemplated by Section 2(e) would continue for
the longer of the Exclusivity Term or duration of the term of the definitive agreement, and (e) the Parties’ commercial operations
will be subject to any applicable license agreements structured in a mutually agreeable manner based on the scope of the Parties’
respective fields, technology and territories. In the event the Parties are unable to reach agreement on such definitive agreement
on or before such [***] period, then, to the extent that either Party wishes to clinically develop or commercialize the combination
of the Compounds and the other Party does not, such other Party will [***].

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

4.          Regulatory,
Quality and Pharmacovigilance.

 

(a)          Regulatory.
As promptly as reasonably practicable following the Effective Date, SpringWorks shall submit a letter to the U.S. Food and Drug
Administration (“FDA”) with respect to SpringWorks’ IND for the SpringWorks Compound permitting the FDA
to access such IND for information about the SpringWorks Compound solely to the extent required for the performance of the Study.
SpringWorks will provide a copy of such letter to BeiGene for BeiGene to submit with respect to the IND for the Study. SpringWorks
will inform BeiGene in a timely manner of any changes to the SpringWorks Compound-related IND, or any guidance provided to investigators
by the FDA relating to the SpringWorks Compound, to the extent regarding: (i) the safety of the SpringWorks Compound; (ii) pharmacology
and non- clinical study results; (iii) updated investigator’s brochure(s); (iv) expedited safety reports; or (v) material
manufacturing changes or issues that would reasonably be expected to affect the SpringWorks Compound supply or quality. BeiGene
will inform SpringWorks in a timely manner of any changes to the BeiGene Compound-related IND, or any guidance provided to investigators
by the FDA relating to the BeiGene Compound, to the extent regarding: (i) the safety of the BeiGene Compound; (ii) pharmacology
and non-clinical study results; (iii) updated investigator’s brochure(s); (iv) expedited safety reports; or (v) material
manufacturing changes or issues that would reasonably be expected to affect the BeiGene Compound supply or quality.

 

(b)          Quality
Agreement. Within forty five (45) days from the Effective Date, the Parties shall enter into a quality agreement that shall
address and govern issues related to the quality of SpringWorks Compound and BeiGene Compound supplied for use in the Study (“Quality
Agreement”). The Quality Agreement shall, among other things: (i) describe each Party’s responsibilities to comply
with cGMP (as cGMP/current good manufacturing practices are defined by applicable national and international regulatory authorities
and advisory boards); (ii) include criteria for release and related certificates and documentation; (iii) include criteria and
timeframes for acceptance of SpringWorks Compound and BeiGene Compound; (iv) detail classification of any non-conformance; (v)
include procedures for the resolution of disputes regarding any SpringWorks Compounds and BeiGene Compounds found to have a non-conformance;
and (vi) include provisions governing the recall of SpringWorks Compound or BeiGene Compound. In the event of any inconsistency
between this Agreement and the Quality Agreement pertaining to quality matters, the Quality Agreement shall control and in all
other circumstances this Agreement shall control. For clarity, where an issue is addressed in either this Agreement or the Quality
Agreement and not addressed in the other, there is no inconsistency.

 

(c)          Pharmacovigilance
Plan. The Parties shall meet to discuss in

 

good faith, as soon as practical following
the Effective Date, and mutually agree upon (no later than sixty (60) days following the Effective Date) a detailed pharmacovigilance
plan relating to the Compounds, which shall set forth standard operating procedures governing the collection, investigation, reporting,
and exchange of information concerning adverse drug reactions/adverse events sufficient to permit each Party to comply with its
regulatory and other legal obligations within applicable timeframes.

     

     

    

 

5.          Commencement
and Termination.

 

(a)          Term.
This Agreement begins on the Effective Date and shall continue in force until the earlier of (i) the date of termination of this
Agreement by either Party in accordance with Section 5(b), (ii) the one-year anniversary of the date that BeiGene provides the
final clinical study report for the Study to SpringWorks or (iii) the date of termination of the Study (the “Term”).

 

(b)          Termination.
Either Party (the “Terminating Party”) may terminate this Agreement as follows: (i) upon thirty (30) days written
notice to the other Party if the Terminating Party entirely ceases all development of its Compound; (ii) upon written notice to
the other Party if the Terminating Party reasonably concludes that there is a patient safety issue with continuing the Study and
has first raised such issue at the JSC; (iii) upon written notice to the other Party if a regulatory authority withdraws approval
for a Compound or the Study; or (iv) upon written notice to the other Party in the event that such other Party is in material breach
of this Agreement and has not cured such breach within thirty (30) days of receipt of a written notice from the Terminating Party
regarding such breach and describing such breach in reasonable detail, subject to final resolution of any breach pursuant to Article
16.

 

(c)          Effects
of Termination. Upon the early termination of this Agreement in accordance with Section 5(b), (i) except as expressly set forth
in this Section (c), each Party’s use of the other Party’s Compound shall immediately terminate; (ii) BeiGene will
immediately stop enrolling subjects into the Study and wind-down the Study, including to cease administering Compounds to Study
subjects and conducting Study procedures on Study subjects, to the extent medically advisable, but in all cases in accordance with
applicable laws, rules and regulations; (iii) the Parties shall submit a final reconciliation of all unpaid Shared Costs as provided
in Section 2(b) and reconcile such unpaid Shared Costs; and (iv) each Party will return all unused Compound of the other Party
to the other Party or destroy such Compound on the other Party’s written request. Notwithstanding the foregoing, in the event
the Term ends pursuant to Section 5(a)(iii), this Agreement shall survive solely with respect to the Fixed Dose Formulation Work,
including, BeiGene’s obligation to supply BeiGene Compound for such purposes, until completion or termination of such Fixed
Dose Formulation Work by SpringWorks; provided, that, such supply shall be provided for a transfer price equal to [***] of BeiGene’s
COGS (as defined in Exhibit E).

 

(d)          Survival.
Notwithstanding the early termination or expiration of this Agreement, Articles 7, 8, 10, 12, 14, 16 and 19 and Sections 2(c),
2(e), the final sentence of Section 3 (until the termination or conclusion of any clinical trial involving the combination of the
Compounds described in Section 3 initiated within one (1) year of such termination or expiration), 5(c), 5(d), 9(b) and 9(c) and
Section 2(d) of Exhibit E shall survive the expiration or termination of this Agreement.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

     

     

    

 

6.          Supply
and Use of Compounds.

 

(a)          Generally.

 

(i)          Supply
by SpringWorks. SpringWorks shall provide BeiGene with the SpringWorks Compound in the form and amounts as set forth in the
Protocol; provided, that, the Protocol has been approved by the JSC, and is being followed by BeiGene (as such Protocol is approved
by any applicable IRB). SpringWorks hereby represents and warrants to BeiGene that, at the time of Delivery (as defined below)
of the SpringWorks Compound, such SpringWorks Compound shall have been manufactured and supplied in compliance with: (A) the specifications
for the SpringWorks Compound (as set forth in applicable regulatory approvals); (B) the Quality Agreement; and (C) all applicable
laws, rules and regulations, including cGMP (as cGMP/current good manufacturing practices are defined by applicable national and
international regulatory authorities and advisory boards) and health, safety and environmental protections. Without limiting the
foregoing, SpringWorks is responsible for obtaining all regulatory approvals (including facility licenses) that are required to
manufacture the SpringWorks Compound in accordance with applicable laws, rules and regulations (provided that, for clarity, BeiGene
shall be responsible for obtaining regulatory approvals for the Study).

 

(ii)         Supply
by BeiGene. BeiGene shall supply the BeiGene Compound in the form and amounts as set forth in the Protocol; provided, that,
the Protocol has been approved by the JSC, and is being followed by BeiGene (as such Protocol is approved by any applicable IRB).
BeiGene hereby represents and warrants to SpringWorks that, at the time the BeiGene Compound is included in the Study, such BeiGene
Compound shall have been manufactured and supplied in compliance with: (A) the specifications for the BeiGene Compound (as set
forth in applicable regulatory approvals); (B) the Quality Agreement; and (C) all applicable laws, rules and regulations, including
cGMP (as cGMP/current good manufacturing practices are defined by applicable national and international regulatory authorities
and advisory boards) and health, safety and environmental protections. Without limiting the foregoing, BeiGene is responsible for
obtaining all regulatory approvals (including facility licenses) that are required to manufacture the BeiGene Compound in accordance
with applicable laws, rules and regulations.

 

(b)          Shelf
Life. SpringWorks shall supply the SpringWorks Compound hereunder (pursuant to one or more Deliveries as contemplated by Section
6(f)) with an adequate remaining shelf life at the time of such Delivery to meet applicable Study requirements for the portion
of the Study for which such SpringWorks Compound is supplied. BeiGene shall supply the BeiGene Compound hereunder (pursuant to
one or more Deliveries as contemplated by Section 6(f)) with an adequate remaining shelf life at the time of Delivery to meet applicable
Study requirements and Fixed Dose Formulation Work requirements for the Fixed Dose Formulation Work or the portion of the Study
for which such BeiGene Compound is supplied.

 

(c)          Delivery.
SpringWorks will deliver the SpringWorks Compound [***] (INCOTERMS 2010) to BeiGene’s, or its designee’s, location
as specified by BeiGene (“Delivery”) with respect to such SpringWorks Compound. BeiGene will: (i) take delivery
of the SpringWorks Compound supplied hereunder; (ii) perform the acceptance procedures allocated to it under the Quality Agreement;
and

 

(i)          subsequently
label and pack the SpringWorks Compound for use at the Study sites. BeiGene will ensure that BeiGene has BeiGene Compound supply
when required at BeiGene’s, or its designee’s, location, to meet applicable Study requirements.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

     

     

    

 

(d)          Storage.
BeiGene agrees to store (or to use commercially reasonable efforts to cause its contract service organization(s) to store) (i)
the SpringWorks Compound supplied by SpringWorks in accordance with any reasonable storage requirements provided to BeiGene by
SpringWorks and (ii) the BeiGene Compound as may be required to meet Study requirements.

 

(e)          Customs.
Consistent with the [***] (INCOTERMS 2010) delivery terms specified in Section 6(c)), SpringWorks will ensure proper storage conditions
for the SpringWorks Compound through customs. Customs documents shall be prepared in due time to secure a smooth transmission through
customs which does not have a material impact on the SpringWorks Compound’s shelf-life.

 

(f)          Logistics.
The Parties will agree on amounts of the SpringWorks Compound needed, on the procedures to be used for labeling, quality control
and testing, and on the time schedules for supply of the SpringWorks Compound, and the Parties will agree on amounts of the BeiGene
Compound needed, on the procedures to be used for labeling, quality control and testing, and on the time schedules for supply of
the BeiGene Compound; provided, that, in any event, such amounts and timing will be adequate for the performance of the Protocol
and Study.

 

(i)          The
SpringWorks Compound shall be supplied in the form and with the documentation as follows:

 

(A)         SpringWorks
Compound packed in [***].

 

(B)         Without
limiting the requirements of the Quality Agreement, documentation for all SpringWorks Compound Delivered hereunder will include:
(1) information on allowable temperature excursions; (2) batch confirmation; (3) TSE certification or TSE statement confirming
no material from animal origin; (4) MSDS sheet (or equivalent) for safe handling information; (5) letter of cross-reference; (6)
documentation to enable release of clinical trial material (e.g. certificate of compliance, certificate of analysis); and (7) an
import license if required.

 

(ii)         The
BeiGene Compound shall be supplied in the form and with the documentation as follows:

 

(A)         BeiGene
Compound packed in [***].

 

(B)         Without
limiting the requirements of the Quality Agreement, documentation for all BeiGene Compound Delivered hereunder will include: (1)
information on allowable temperature excursions; (2) batch confirmation; (3) TSE certification or TSE statement confirming no material
from animal origin; (4) MSDS sheet (or equivalent) for safe handling information; (5) letter of cross-reference;

 

(6) documentation to enable release of
clinical trial material (e.g. certificate of compliance, certificate of analysis); and (7) an import license if required.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

(iii)        BeiGene
will provide SpringWorks with an IND number (for shipments of clinical material to the United States) and CTN number (for shipments
of clinical material to Australia). BeiGene will obtain and maintain the documentation provided by SpringWorks as described in
the foregoing clause (i)(B), and the IND and CTN numbers for BeiGene Compound.

 

(g)          Deviations.
Subject to the terms and conditions of the Quality Agreement,

 

(i)          SpringWorks
will notify BeiGene of any deviations, nonconformance, out of specification result or quality incident which has the potential
to impact product quality or safety of the SpringWorks Compound or which otherwise indicates that the SpringWorks Compound may
not meet the agreed upon quality standards and SpringWorks shall replace any such non-conforming SpringWorks Compound as soon as
possible following provision of such notice to BeiGene.

 

(ii)         BeiGene
will notify SpringWorks of any deviations or quality incident which it observes after the SpringWorks Compound has been Delivered
to BeiGene which indicates that the SpringWorks Compound may not meet the agreed upon quality standards and SpringWorks shall replace
any such non-conforming SpringWorks Compound as soon as possible following receipt of such notice from BeiGene, unless the deviation,
non-conformance, out of specification result or quality incident is due to BeiGene.

 

(iii)        BeiGene
will notify SpringWorks of any deviations, nonconformance, out of specification result or quality incident which has the potential
to impact product quality or safety of any BeiGene Compound t or which otherwise indicates that the BeiGene Compound may not meet
the agreed upon quality standards and BeiGene shall replace any such non-conforming BeiGene Compound as soon as possible following
provision of such notice to SpringWorks.

 

(iv)        BeiGene
will notify SpringWorks of any deviations or quality incident which it observes after the BeiGene Compound has been committed to
the Study which indicates that the BeiGene Compound may not meet the agreed upon quality standards and BeiGene shall replace any
such non-conforming BeiGene Compound as soon as possible following delivery of such notice to SpringWorks.

 

(v)         SpringWorks
will notify BeiGene of any deviations or quality incident which it observes after the BeiGene Compound has been delivered to SpringWorks
which indicates that the BeiGene Compound may not meet the agreed upon quality standards and BeiGene shall replace any such non-conforming
BeiGene Compound as soon as possible following receipt of such notice from SpringWorks, unless the deviation, non-conformance,
out of specification result or quality incident is due to SpringWorks.

 

     

     

    

 

(h)          Recalls.
The decision to initiate a recall or withdrawal of the SpringWorks Compound will be, as between the Parties, the responsibility
of SpringWorks at its sole cost and expense. The decision to initiate a recall or withdrawal of the BeiGene Compound will be, as
between the Parties, the responsibility of BeiGene at its sole cost and expense. The responsibility for the actual stock recovery
will be BeiGene’s. If a potential recall or withdrawal situation arises due to reasons associated with the SpringWorks Compound
not as a result of any subsequent actions carried out by BeiGene, then SpringWorks will contact BeiGene as soon as possible to
begin the recall or withdrawal process. If a potential recall or withdrawal situation arises due to reasons associated with the
BeiGene Compound, then BeiGene will contact SpringWorks as soon as possible and begin the recall or withdrawal process immediately
thereafter. If a situation arises that BeiGene reasonably determines necessitates a recall or withdrawal of SpringWorks Compound
supplies from the Study sites, SpringWorks shall review the situation with BeiGene prior to initiating the retrieval. In the event
that any recall or withdrawal of a SpringWorks Compound is undertaken for reasons relating to SpringWorks’ failure to manufacture
or deliver such SpringWorks Compound in accordance with its specifications, this Agreement or the Quality Agreement, SpringWorks
shall be responsible for the reasonable costs (both internal and external) that BeiGene incurs in connection with undertaking such
recall or withdrawal. If a situation arises that BeiGene reasonably determines necessitates a recall or withdrawal of BeiGene Compound
supplies from the Study sites, BeiGene shall review the situation with SpringWorks prior to initiating the retrieval. In the event
that any recall or withdrawal of a BeiGene Compound is undertaken for reasons relating to BeiGene’s failure to manufacture
or deliver such BeiGene Compound in accordance with its specifications, this Agreement or the Quality Agreement, BeiGene shall
be responsible for the costs (both internal and external) that BeiGene incurs in connection with undertaking such recall or withdrawal.

 

7.          Confidentiality.

 

(a)          Obligations.
BeiGene and SpringWorks each agrees to hold in

 

confidence any Confidential Information
(as defined below) provided by the other Party or its respective Affiliates (“Disclosing Party”) to each such
Party (“Receiving Party”) and the Receiving Party shall not use Confidential Information of the Disclosing Party
except for purposes of conducting the Study and performing such Party’s obligations, and exercising such Party’s rights,
under this Agreement. The Receiving Party shall not, without the prior written permission of the Disclosing Party, disclose any
Confidential Information to any third party except to the extent disclosure may be required by applicable law or as necessary for
the conduct of the Study and provided that the Disclosing Party shall, to the extent reasonably practicable, provide reasonable
advance notice to the other Party before making such disclosure, and provided, further, that such necessary disclosures to a third
party will be under a written confidentiality agreement consistent with this Article 7. An “Affiliate” of a
Party shall mean: (i) organizations, which directly or indirectly control such Party; (ii) organizations, which are directly or
indirectly controlled by such Party; and (iii) organizations, which are controlled, directly or indirectly, by the ultimate parent
company of such Party and “control” as used in the foregoing clauses (i) through (iii) is defined as owning more than
50% of the voting stock of a company or having otherwise the power to govern the financial and the operating policies or to appoint
the management of an organization.

 

     

     

    

 

(b)          Confidential
Information.         “Confidential Information” means
any information of a Party that is not presently in the public domain, and is disclosed by the Disclosing Party to the Receiving
Party pursuant to this Agreement. The Study Results and Joint Inventions, and the terms of this Agreement, will be treated as Confidential
Information of each Party (and only clause (ii) below will apply to the Study Results and Joint Inventions). The obligations of
a Receiving Party as set forth in this Article 6 shall not extend to any portion of the Disclosing Party’s Confidential Information
which: (i) is disclosed to the Receiving Party by a third party who has no obligation of confidentiality to the Disclosing Party
with respect thereto; or (ii) is or becomes lawfully part of the public domain or otherwise available to the public by reason of
acts not attributable to the Receiving Party; or (iii) is developed independently by the Receiving Party without access to or use
of the Disclosing Party’s Confidential Information; or (iv) is in the Receiving Party’s possession prior to disclosure
by the Disclosing Party as evidenced by the Receiving Party’s written records.

 

(c)          Limited
Disclosure. Each Receiving Party shall only share the other Party’s Confidential Information (including, for clarity,
any Confidential Information that is Confidential Information of both Parties) (i) within its organization to those individuals
who need to know such information for purposes of performing its obligations under this Agreement and who are bound by written
obligations of confidentiality and non-use no less restrictive than those contained herein, and (ii) to any bona fide actual
or prospective acquirers, underwriters, investors, lenders or other financing sources, and any bona fide actual or prospective
subcontractors, collaborators, licensors, sublicensees, licensees, or strategic partners, and to employees, directors, agents,
consultants, and advisers of any such third parties, in each case, and who are bound by written obligations of confidentiality
and non-use no less restrictive than those contained herein (but for this clause (ii) of duration customary in confidentiality
agreements entered into for a similar purpose).

 

(d)          Duration.
The confidentiality, non-use and non-disclosure obligations of this Agreement shall remain effective for a period of seven (7)
years after termination or expiration of this Agreement; provided, that, any Confidential Information which constitutes a trade
secret of a Party shall remain subject to this Section for as long as such Confidential Information continues to qualify as a trade
secret under applicable law.

 

(e)          Personal
Identifiable Data. All Confidential Information containing personal identifiable data shall be handled in accordance with all
data protection and privacy laws, rules and regulations applicable to such data.

 

(f)          Prior
CDAs. All Confidential Information disclosed by either Party or their Affiliates under that certain Mutual Confidentiality
Agreement dated October 10, 2017 (the “CDA”) pertaining to subject matter within the scope of this Agreement
will be treated as “Confidential Information” hereunder. The CDA will continue in full force and effect as applied
to a Party and its Affiliates with respect to subject matter outside the scope of this Agreement.

     

     

    

 

8.          Intellectual
Property and Patents.

 

(a)          Data
and Results. All data and results generated in or otherwise arising from performing the Study or the Fixed Dose Formulation
Work, including all analyses prepared with respect thereto (collectively, “Study Results”) shall be jointly
owned by the Parties and shall be deemed “Joint Inventions” for purposes of this Agreement. BeiGene agrees to provide
SpringWorks with the Study Results via electronic data transfer in SAS format or as otherwise agreed by the Parties on a monthly
basis. The Parties, working through the JSC shall prepare a draft clinical study report and “Tables, Figures and Listings”
in connection with the Study and a copy of the final report for the Study. Neither Party will disclose any of the foregoing, or
any of the Study Results or Joint Inventions, under confidentiality or otherwise, before disclosing same to the other Party at
least thirty (30) days before any disclosure to any others (but in all events subject to any disclosure required by applicable
law). Further, neither Party nor its Affiliates will disclose to any others, practice or otherwise use (including filing with any
regulatory agency or IRB) any of the Study Results or Joint Inventions (even if public) except with the prior, written consent
of the other Party (in its sole discretion), or as follows: (i) as expressly permitted under Article 9 or the remainder of this
Article 8, (ii) to perform the Study or Fixed Dose Formulation Work, (ii) for its and its Affiliates’ own internal evaluations
with respect to the Compounds and their use, (iii) to the extent required by applicable law, including in connection with any regulatory
or other governmental filing to support such Party’s Compound (including in combination with any other therapeutic agents,
but in all events without the other Compound), or (iv) if confidential, under confidentiality as required by Article 6 (including
to third parties as provided in such Article). Without limiting the generality of the foregoing, absent further written agreement
between the Parties, neither Party (nor any of their Affiliates or subcontractors, licensees or sublicensees) shall file or use
any of the Study Results or Joint Inventions to support the clinical development or approval of any drug candidate, other than
such Party’s Compound (including in combination with any other therapeutic agents, but in all events, (x) other than as set
forth in Section 2(e) and (y) without the other Compound), unless required by law.

 

(b)          Joint
Inventions.

 

(i)          BeiGene
and SpringWorks agree that all rights to all (1) Study Results and (2) inventions and discoveries made or conceived in the course
of the Study relating to the combination of, or the use together of, the BeiGene Compound and SpringWorks Compound shall belong
jointly to BeiGene and SpringWorks (each of (1) and (2), “Joint Inventions”). BeiGene hereby assigns (and if
such assignment cannot now be made hereby agrees to assign) to SpringWorks an undivided one-half interest in, to and under the
Joint Inventions (and patent and other intellectual property rights arising therefrom) that are invented or created solely or jointly
by BeiGene or by persons having an obligation to assign such rights to BeiGene or who otherwise worked on behalf of BeiGene under
this Agreement. SpringWorks hereby assigns (and if such assignment cannot now be made hereby agrees to assign) to BeiGene an undivided
one- half interest in, to and under any Joint Inventions (and patent and other intellectual property rights arising therefrom)
that are invented or created solely or jointly by SpringWorks or by persons having an obligation to assign such rights to SpringWorks
or who otherwise worked on behalf of SpringWorks under this Agreement.

 

(ii)         If
both Parties desire to file a patent application in respect of any Joint Invention (a “Joint Patent”), the Parties
will do so at their joint expense and assist each other in the preparation, filing and prosecution of such Joint Patent application
shall be discussed in good faith between the Parties and no patent application in respect of such Joint Invention may be filed
without the agreement of the Parties; provided, that, if one Party does not desire to file a patent covering any such Joint Invention,
then no such patent may be pursued without the other Party’s prior written consent (which may be withheld in its sole discretion).
Subject to the foregoing proviso, the terms of this Agreement, and any other agreement between the Parties, BeiGene and SpringWorks
shall each be entitled to use said Joint Inventions and Joint Patent without accounting to the other Party and without the consent
of the other Party. Without limiting the foregoing, in the event that the Parties cannot agree regarding which Party should be
responsible for filing for, and maintaining, a Joint Patent, neither Party shall have any tie-breaking vote but such matter will
instead be subject to Article 16.

 

     

     

    

 

(iii)        The
enforcement and defense of any Joint Patent will be subject to further agreement between the Parties; absent agreement, the following
shall apply: BeiGene shall have the first right to initiate legal action to enforce all Joint Patents against infringement or misappropriation
by any third party that is marketing, or seeking to market, a compound in the same class as the BeiGene Compound, or to defend
any declaratory judgment action relating thereto, at its sole expense. In the event that BeiGene fails to initiate or defend such
action within thirty (30) days after being first notified of such infringement, SpringWorks shall have the right to do so at its
sole expense. Similarly, SpringWorks shall have the first right to initiate legal action to enforce all Joint Patents against infringement
or misappropriation by any third party that is marketing, or seeking to market, a compound in the same class as the SpringWorks
Compound or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that SpringWorks fails
to initiate or defend such action within thirty (30) days after being first notified of such infringement, BeiGene shall have the
right to do so at its sole expense.

 

(c)          Sole
Inventions. The Parties agree that all rights, title and interest in and to inventions and discoveries relating solely to the
BeiGene Compound (and its use) that are made or conceived in the course of the Study (by or on behalf of BeiGene, SpringWorks,
or jointly) (“BeiGene Compound Inventions”), will be the exclusive property of BeiGene and BeiGene shall be
entitled to file in its own name relevant patent applications and to own resultant patent rights for such inventions, and, no license
is granted to SpringWorks with respect thereto. The Parties agree that all rights, title and interest in and to inventions and
discoveries relating solely to the SpringWorks Compound (and its use) that are made or conceived in the course of the Study (by
or on behalf of BeiGene, SpringWorks, or jointly) (“SpringWorks Compound Inventions”), will be the exclusive
property of SpringWorks and SpringWorks shall be entitled to file in its own name relevant patent applications and to own resultant
patent rights for such inventions, and, no license is granted to BeiGene with respect thereto.

 

(d)          Assistance.
To the extent that any right, title or interest in or to any inventions and discoveries discovered, invented, created or otherwise
generated under this Agreement (including Joint Inventions and Joint Patents) vests in a Party or its Affiliate, by operation of
law or otherwise, in a manner contrary to the agreed upon ownership as set forth in this Agreement (including under Section 8(a),
8(b)(i)and 8(c)), such Party (or its Affiliate) shall, and hereby does, and agrees to if not now possible, irrevocably assigns
to the other Party any and all such right (including all intellectual property rights), title and interest in, to and under such
inventions or discoveries to the other Party without the need for any further action by any Party. All of the employees, officers
and consultants of each Party that are engaged in the performance of its obligations or exercise of its rights under this Agreement
(and any other third parties engaged by such Party) shall have executed agreements assigning to such Party all inventions and other
inventions and discoveries discovered, invented, created or otherwise generated during the course of and as the result of their
association with such Party, obligating the individual upon request to sign any documents to confirm or perfect such assignment
and to cooperate in the preparation and prosecution of any patent applications disclosing or claiming such inventions. When a Party
is prosecuting and maintaining any patent or patent application in accordance with the foregoing Section 8(a), (b) or (c), as applicable,
or is enforcing a patent right or defending an action as described in Section 8(b) with respect to any Joint Patent, then upon
reasonable request by such Party, the other Party shall reasonably assist in such prosecution, maintenance, defense, or enforcement,
as applicable, at the requesting Party’s reasonable costs, including if required or desirable, furnishing documents and information,
and executing all necessary documents as the requesting Party may reasonably request or joining any such enforcement action as
a party plaintiff.

 

     

     

    

 

(e)          Limitations
on use of Confidential Information. BeiGene agrees to make no patent application based on SpringWorks Confidential Information,
and SpringWorks agrees to make no patent application based on BeiGene Confidential Information, absent further written agreement
between the Parties.

 

(f)           No
Implied License. Except for the rights expressly granted under this Agreement (including the right for SpringWorks to use the
BeiGene Compound solely for purposes of performing the Fixed Dose Formulation Work and performing its obligations with respect
to the Study, for BeiGene to use the SpringWorks Compound solely for purposes of performing the Study or for a Party to use Compound
supplied pursuant to Section 3), no right or license is granted by either Party to the other Party hereunder whether by implication,
estoppel, or otherwise to any know-how, patent or other intellectual property right owned or controlled by such Party or its Affiliates,
including the BeiGene IP and SpringWorks IP. All rights with respect to technology, know-how or intellectual property rights that
are not specifically granted herein are reserved to the owner of such technology, know-how or intellectual property rights.

 

(g)          Effect
of Compound Spin-Out Transaction. [***].

 

9.          Registration;
Publicity; Securities Filings and Publications.

 

(a)          Registration.
BeiGene will register the Study with the FDA’s Clinical Trials Registry (www.clinicaltrials.gov)
and is committed to timely publication of the results of the Study following its completion.

 

(b)          Publicity.
Except as required by applicable laws and except for the joint press release in the form to be mutually agreed and issued by the
Parties within thirty (30) days of the Effective Date, (i) each Party agrees not to issue any press release or other public statement,
whether oral or written, disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement
without the prior written consent of the other Party and (ii) neither Party shall use the name, insignia, symbol, trademark, trade
name or logotype of the other Party or its Affiliates in any publication, press release, promotional material or other form of
publicity without the prior written consent of the other Party, in each case ((i) and (ii) which shall not be unreasonably withheld
or delayed, except for those disclosures for which consent has previously been obtained or as otherwise provided herein.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

(c)          Securities
Filings. Each Party acknowledges and agrees that the other Party may submit a copy of this Agreement to, and/or include a description
of the material terms of this Agreement in any filing with, the U.S. Securities and Exchange Commission or any national securities
exchange in any jurisdiction, or to such other persons as may be required by applicable laws; provided, that, (i) if such Party
intends to submit a copy of this Agreement, such Party shall (A) reasonably consult and coordinate with the other Party with respect
to the preparation and submission of a confidential treatment request for this Agreement and (B) if the other Party provides any
comments to the proposed confidential treatment request, in good faith consider incorporating such comments and (ii) if such Party
intends to include a disclosure of the material terms of this Agreement in any such filing or other submission, such Party shall
(A) provide copies of the proposed disclosure to the other Party reasonably in advance of such filing or other submission and (B)
if the other Party provides any comments to the proposed disclosure, in good faith consider incorporating such comments. Notwithstanding
the foregoing, neither Party shall disclose Confidential Information of the other Party (other than this Agreement, including the
terms hereof, as provided above) in any such submission or filing without the prior written consent of such other Party, which
shall not be unreasonably withheld or delayed.

 

(d)          Publications.
The Parties agree that prior to submission of the results of the Study or other Study Results for publication or presentation or
any other dissemination of results including oral dissemination, the Party desiring to make such publication or presentation (the
“Publishing Party”) shall inform the other Party (the “Reviewing Party”) regarding the content
of the material to be published or presented, and the Reviewing Party’s prior written consent (in the Reviewing Party’s
sole discretion) shall be required before any such publication or presentation, unless otherwise required by law. Without limiting
the generality of the foregoing, the Publishing Party agrees not to include Confidential Information disclosed by the Reviewing
Party to the Publishing Party pursuant to this Agreement in any publication without the prior written consent of the Reviewing
Party (in the Reviewing Party’s sole discretion). If the Reviewing Party does not otherwise notify the Publishing Party of
any objection to the publication or presentation within forty-five (45) days of being informed thereof by the Publishing Party,
then the Reviewing Party shall be deemed to have granted such approval upon expiration of such period.

 

(i)          The
Publishing Party agrees to include in all press releases, presentations and publications it makes related to a Study, specific
mention, if applicable of the BeiGene Compound, when SpringWorks is the Publishing Party, or the SpringWorks Compound, when BeiGene
is the Publishing Party. Even after any publication of any of the Study Results, each Party and its Affiliates will continue to
be subject to the restrictions set forth in Section 8(a), to the extent applicable.

 

(e)          Required
Disclosures. The Receiving Party may disclose the Disclosing Party’s Confidential Information, and each Party may disclose
this Agreement, to the extent required by law or court order; provided, however, that the Party subject to such requirement promptly
provides to the other Party prior written notice of such disclosure and provides reasonable assistance in obtaining an order or
other remedy protecting the other Party’s Confidential Information, or this Agreement, from public disclosure or limiting
the other Party’s Confidential Information, or the portions of this Agreement, so disclosed.

 

     

     

    

 

10.         Indemnification;
Insurance.

 

(a)          By
SpringWorks. SpringWorks agrees to defend, indemnify and hold BeiGene and its Affiliates and their respective officers, employees,
consultants or agents, harmless from and against all third party loss, damages, reasonable costs and expenses (including reasonable
attorney’s fees and expenses) incurred in connection with any claim, proceeding, or investigation arising out of (i) the
breach of this Agreement; (ii) any gross negligence or willful misconduct of SpringWorks; (iii) the manufacturing, packaging or
labeling of the SpringWorks Compound by or on behalf of SpringWorks; or (iv) the use of the SpringWorks Compound separate and apart
from the BeiGene Compound; provided, however, that such indemnification, defense, and hold harmless obligations shall not extend
to claims, proceedings or investigations subject to indemnification by BeiGene under Section 10(b).

 

(b)          By
BeiGene. BeiGene agrees to defend, indemnify and hold SpringWorks and its Affiliates and their respective officers, employees,
consultants or agents, harmless from and against all third party loss, damages, reasonable costs and expenses (including reasonable
attorney’s fees and expenses) incurred in connection with any claim, proceeding, or investigation brought by any third party
and arising out of (i) the breach of this Agreement; (ii) any gross negligence or willful misconduct of BeiGene; (iii) the manufacturing,
packaging or labeling of the BeiGene Compound; or

 

(i)          the
use of the BeiGene Compound separate and apart from the SpringWorks Compound; provided, however, that such indemnification, defense,
and hold harmless obligations shall not extend to claims, proceedings or investigations subject to indemnification by SpringWorks
under Section 10(a).

 

(c)          Limitations.
Notwithstanding Sections 10(a) and 10(b), each Party’s indemnification, defense and hold harmless obligations: (i) are subject
to the compliance by all indemnified parties with applicable law; and (ii) do not apply to cover any liabilities resulting from
a grossly negligent or wrongful act or failure to act on the part of any indemnified Party.

 

(d)          Procedures.
A Party seeking indemnification shall promptly inform the other Party in writing of any claim or lawsuit which comes to the attention
of the Party seeking indemnification and which could potentially give rise to a claim for indemnity against the other Party, shall
not settle or compromise any claim without the written consent of the other Party, and shall assist and cooperate with the other
Party in the investigation and defense of any claim. The indemnifying Party shall assume control of the defense and settlement
of the claim, provided that the indemnified Party shall have the right to participate in such defense and any settlement negotiations
with counsel of its own selection, at its sole expense.

 

(e)          Insurance.
Prior to commencement of (i) the Study or (ii) Fixed Dose Formulation Work, whichever of (i) or (ii) shall first occur, each Party
shall procure and maintain insurance, including product liability insurance, or shall self-insure, in each case in a manner adequate
to cover its obligations under this Agreement and consistent with normal business practices of prudent companies similarly situated
at all times during the Term and for a period of five (5) years thereafter.

 

     

     

    

 

(f)          Disclaimers.
WITH RESPECT TO MATTERS PERTAINING TO THIS AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES OR THEIR RESPECTIVE OFFICERS, DIRECTORS,
EMPLOYEES, AGENTS, OR REPRESENTATIVES WILL BE LIABLE FOR, NOR WILL THE MEASURE OF DAMAGES INCLUDE ANY INCIDENTAL, SPECIAL, CONSEQUENTIAL
INDIRECT OR PUNITIVE DAMAGES OR AMOUNTS FOR LOSS OF INCOME, PROFITS OR SAVINGS, LOSS OF CONTRACTS OR OPPORTUNITY, OR COST OF CAPITAL
REGARDLESS OF THE BASIS ON WHICH A PARTY IS ENTITLED TO CLAIM DAMAGES, WHETHER IN CONTRACT OR TORT (INCLUDING BREACH OF WARRANTY,
NEGLIGENCE AND STRICT LIABILITY), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE. LIMITATIONS
OR EXCLUSIONS OF LIABILITY HEREUNDER DO NOT APPLY TO THE PARTIES’ INDEMNIFICATION OBLIGATIONS AND CONFIDENTIALITY AND NON-USE
OBLIGATIONS AND OBLIGATIONS UNDER SECTIONS 2(e), 8(a)(ii), AND 8(e).

 

NEITHER PARTY REPRESENTS THAT THE STUDY
SHALL LEAD TO ANY PARTICULAR RESULT, NOR IS THE SUCCESS OF THE STUDY GUARANTEED. NEITHER PARTY SHALL BE LIABLE FOR ANY USE THAT
THE OTHER PARTY MAY MAKE OF THE CLINICAL DATA OR STUDY RESULTS NOR FOR ADVICE OR INFORMATION GIVEN IN CONNECTION THEREWITH.

 

11.         Force
Majeure. If the performance of this Agreement by one of the Parties is prevented, hindered or delayed by reason of any cause
beyond this Party’s control (war, riots, fire, strike, governmental laws), this Party shall be excused from performance to
the extent that is necessarily prevented, hindered or delayed.

 

12.         Complete
Agreement; Modification. The Parties agree to the full and complete performance of the mutual covenants contained in this Agreement.
This Agreement constitutes the sole, full and complete Agreement by and between the Parties with respect to the subject matter
of this Agreement. No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless
reduced to writing, signed by the Parties and attached hereto.

 

13.         Assignment.
Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party. Notwithstanding the
foregoing, (a) all rights and obligations of either Party may be exercised or performed by its Affiliates, provided the contracting
Party hereto remains primarily responsible for the performance of such Affiliate in accordance with the terms and conditions of
this Agreement, the contracting Party waives any right that the other Party pursue any claims against any such Affiliate prior
to pursuing a claim against the contracting Party, and the contracting Party shall have the sole right to pursue a claim against
the other Party on behalf of itself or its Affiliates, and (b) either Party shall have the right, without the prior consent of
the other Party, to assign this Agreement in full to (i) any Affiliate, provided the contracting Party hereto remains primarily
responsible for the performance of such Affiliate in accordance with the terms and conditions of this Agreement and the contracting
Party waives any right that the other Party pursue any claims against any such Affiliate prior to pursuing a claim against the
contracting Party (ii) any third party in connection with a sale of all or substantially all of the assigning Party’s assets,
or in connection with a merger, transfer of a going concern, sale of stock or other similar transaction (including by operation
of law), in each case upon notice to the other Party or (iii) to any Affiliate or third party as part of a Compound Spin-Out Transaction
pursuant to Section 8(g).

 

14.         Invalid
Provision or Gaps. If single provisions of this Agreement are or become invalid or if there is a gap in the Agreement, the
validity of the other provisions shall not be affected. In lieu of the invalid provision or in order to eliminate the gap, the
Parties shall negotiate in good faith to agree upon a reasonable provision to carry out as nearly as practicable the original intention
of the entire Agreement.

 

     

     

    

 

15.         Representations.
Each of BeiGene and SpringWorks warrant and represent to the other that: (a) it has the corporate power and authority and the legal
right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all necessary corporate action on its
part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; (c) this
Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of
such Party that is enforceable against it in accordance with its terms; and (d) it has not been, and its principals have not been,
debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. §335a(a) and (b), or sanctioned by a
U.S. Federal Health Care Program (as defined in 42 U.S.C. Sec. 1320 a-7b(f)), including the U.S. federal Medicare or a U.S. state
Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any U.S. federal agency or program. In
the event that during the Term, either Party (i) becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible;
or (ii) receives notice of an action or threat of an action with respect to any such debarment, suspension, exclusion, sanction,
or ineligibility, such Party shall immediately notify the other Party. Either Party also agrees that, in the event that either
it or its principals becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible, it shall immediately
notify the other Party and the other Party shall have the right to terminate this Agreement pursuant to Section 4(b)(iv) without
providing an additional cure period.

 

16.         Governing
Law and Jurisdiction. The validity, construction and performance of this Agreement will be governed by and construed for all
purposes in accordance with the laws of the State of New York without regard to conflict of laws principles. The Parties shall
attempt to settle all disputes arising out of or in connection with the present Agreement in an amicable way. Each of the Parties
hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement
or the transactions contemplated hereby in the state courts located in the Borough of Manhattan, New York and to the United States
District Court for the Southern District of New York as the initial filing court and hereby further irrevocably and unconditionally
waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an
inconvenient forum.

 

17.         No
Limitation. Nothing in this Agreement shall (a) prohibit either Party from performing clinical studies other than the Study
relating to its own Compound, either individually or in combination with any other compound or product, in any therapeutic area,
or (b) create an exclusive relationship between the Parties with respect to any Compound, in each case ((a) and (b)) other than
as set forth in Section 2(e).

 

18.         Counterparts
and Due Execution. This Agreement and any amendment may be executed in two or more counterparts (including by way of facsimile
or electronic transmission), each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or
printers. When executed by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic
transmission, storage and printing of copies of this Agreement from computers or printers. For clarity, facsimile signatures and
signatures transmitted via PDF shall be treated as original signatures.

 

     

     

    

 

19.         Construction.
Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the
use of any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement
or the intent of any provision contained in this Agreement. References hereunder to “applicable law” include applicable
rules and regulations, and to “third party(ies)” refer to non-Affiliated third party(ies). Use of “hereunder”
or “herein” refers to this Agreement as a whole. The term “including” as used herein shall be deemed to
be followed by the phrase “without limitation” or like expression. The term “will” as used herein means
shall. References to “Article” or “Section” are references to the numbered sections of this Agreement and
the appendices attached to this Agreement, unless expressly stated otherwise. Except where the context otherwise requires, references
to this “Agreement” shall include the appendices attached to this Agreement. The language of this Agreement shall be
deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied against either Party
hereto.

 

[Remainder of page intentionally left
blank.]

 

     

     

    

 

IN WITNESS WHEREOF,
the respective authorized representatives of the Parties have executed this Agreement as of the Effective Date.

 

BeiGene, Ltd.

 

	/s/ John V. Oyler	 
	Signature	 
	 	 
	John V. Oyler	 
	Name	 
	 	 
	Chief Executive Officer	 
	Title	 
	 	 
	SpringWorks Subsidiary 3, PBC	 
	 	 
	/s/ Saqib Islam	 
	Signature	 
	 	 
	Saqib Islam	 
	Name	 
	 	 
	Chief Executive Officer	 
	Title	 

 

     

     

    

 

Exhibit A

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

Exhibit B

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

Exhibit C

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

Exhibit D

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

Exhibit E

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

     

     

    

 

Exhibit F

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.Exhibit 10.11

 

CONFIDENTIAL

 

CLINICAL TRIAL COLLABORATION AND SUPPLY
AGREEMENT

 

This CLINICAL TRIAL COLLABORATION
AND SUPPLY AGREEMENT (this “Agreement”), made as of 25 June, 2019 (the “Effective Date”),
is by and between GlaxoSmithKline LLC, a Delaware limited liability company, having a place of business at 1250 South Collegeville
Road, Collegeville, PA 19426 (“GSK”) and SpringWorks Therapeutics, Inc., a Delaware corporation, having a place
of business at 100 Washington Blvd., 5th Floor, Stamford, CT 06902 (“SpringWorks”). SpringWorks and
GSK are each referred to herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

		A.	WHEREAS, GSK is developing Belantamab Mafodotin, a humanized (IgG1) antibody drug conjugate that
binds specifically to a B-cell maturation antigen for the treatment of multiple myeloma, other plasma cell clone disorders and
B-cell malignancies (the “GSK Compound”);

 

		B.	WHEREAS, SpringWorks is developing Nirogacestat, a gamma secretase inhibitor (GSI) which specifically
downregulates NOTCH target gene expression and reduces cleavage of B-cell maturation antigen for the treatment of certain human
tumors (the “SpringWorks Compound”);

 

		C.	WHEREAS, GSK desires to sponsor a combination clinical trial combining the GSK Compound and the
SpringWorks Compound to develop a combination therapy for the treatment of multiple myeloma on the terms and conditions set forth
herein; and

 

		D.	WHEREAS, SpringWorks desires to supply the SpringWorks Compound to GSK for use in connection with
the conduct of such combination clinical trial on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the premises and of the following mutual promises, covenants and conditions, the Parties, intending to be legally bound, mutually
agree as follows:

 

		1.	DEFINITIONS.

 

For all purposes of this Agreement,
the capitalized terms defined in this Article 1 and throughout this Agreement shall have the meanings herein specified.

 

		1.1	“Affiliate” means, with respect to either Party, a firm, corporation or other
entity which directly or indirectly owns or controls said Party, or is owned or controlled by said Party, or is under common ownership
or control with said Party. The word “control” means (a) the direct or indirect ownership of fifty percent (50%)
or more of the outstanding voting securities of a legal entity, or (b) possession, directly or indirectly, of the power to direct
the management or policies of a legal entity, whether through the ownership of voting securities, contract rights, voting rights,
corporate governance or otherwise.

 

		1.2	“Agreement” has the meaning set forth in the preamble.

 

    	Page 1 of 73

     

    

 

		1.3	“Applicable Law” means all federal, state, local, national and regional statutes,
laws, rules, regulations and directives applicable to a particular activity hereunder, including performance of clinical trials,
medical treatment and the processing and protection of personal and medical data, that may be in effect from time to time including
those promulgated by the United States Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”)
and any successor agency to the FDA or EMA or any agency or authority performing some or all of the functions of the FDA or EMA
in any jurisdiction outside the United States or the European Union (each a “Regulatory Authority” and collectively,
“Regulatory Authorities”), and including cGMP and GCP; Data Protection Laws; export control and economic sanctions
regulations which prohibit the shipment of United States-origin products and technology to certain restricted countries, entities
and individuals; anti-bribery and anti-corruption laws and regulations governing payments to healthcare providers, including the
Physician Payment Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure
Code; and any United States or other country’s or jurisdiction’s successor or replacement statutes, laws, rules, regulations
and directives relating to the foregoing.

 

		1.4	“Approved Vendor(s)” shall have the meaning given in Section 9.3.

 

		1.5	“Bioanalytical Testing” shall have the meaning given in Section 9.3.

 

		1.6	“Biomarkers” mean any naturally occurring molecule, gene or characteristic by
which a particular pathological or physiological process can be identified and serially monitored during a therapeutic intervention,
including blood (including cells, RNA and circulating multiple myeloma cells (CMMCs)), serum (including cytokines and sBCMA), plasma
(including cfDNA), tissue and tumors (including FFPE bone marrow aspirate and biopsy Samples).

 

		1.7	“Biomarker Testing” shall have the meaning given in Section 9.2.

 

		1.8	“Business Day” means any day other than (a) a Saturday, Sunday or any public
holiday in the country where the applicable obligations are to be performed; and (b) a day falling within the time period from
and including 24 December up to and including 01 January.

 

		1.9	“cGMP” means the current Good Manufacturing Practices officially published and
interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect from time to time and are applicable
to the Manufacture of the Compounds. These include requirements set forth in FDA’s regulations at 21 CFR Parts 11, 210, 211
and 600, as applicable to the processing, manufacture, handling, receipt, packaging, labelling, release and distribution of products
and services subject to this Agreement.

 

		1.10	“Clinical Data” means all data (including raw data) and results generated under
the Sub-Study, including all Sample Testing Results.

 

		1.11	“Clinical Hold” means that (a) the FDA has issued an order to a Party pursuant
to 21 CFR 312.42to delay a proposed clinical investigation or to suspend an ongoing clinical investigation of the Combination
Therapy or such Party’s Compound in the United States, or (b) a Regulatory Authority other than the FDA has issued an equivalent
order to that set forth in (a) in any other country or group of countries.

 

    	Page 2 of 73

     

    

 

		1.12	“Clinical Quality Agreement” means that certain Clinical Quality Agreement entered
into by the Parties pursuant to Section 11.1 hereof.

 

		1.13	“Combination Therapy” means the use or method of using the GSK Compound and
the SpringWorks Compound in combination, whether such administration is concomitant or sequential administration. For the avoidance
of doubt, the Combination Therapy does not include any compounds other than the GSK Compound and the SpringWorks Compound.

 

		1.14	“Compounds” means the GSK Compound and the SpringWorks Compound. A “Compound”
means any of the GSK Compound or the SpringWorks Compound, as applicable.

 

		1.15	“Confidential Information” means any information, Know-How or other proprietary
information or materials, whether in written, visual, oral or electronic or any other format, both technical and non-technical,
disclosed to one Party by the other Party pursuant to this Agreement or prior to the Effective Date or otherwise belonging to a
Party pursuant to this Agreement and relating to matters contemplated by this Agreement, except to the extent that it can be established
by the receiving Party that such information or materials: (a) were already known to the receiving Party, other than under an obligation
of confidentiality, either (i) at the time of disclosure by the other Party, or (ii) if applicable, at the time that it was generated
hereunder, whichever of (i) or (ii) is earlier, in each case as demonstrated by competent business records; (b) were generally
available to the public or otherwise part of the public domain either (i) at the time of its disclosure to the receiving Party,
or (ii) if applicable, at the time that it was generated hereunder, whichever of (i) or (ii) is earlier; (c) became generally available
to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving
Party in breach of this Agreement; (d) were disclosed to the receiving Party by a Third Party who had no obligation to the disclosing
Party not to disclose such information to others; or (e) were subsequently independently developed by the receiving Party (or its
Affiliates) without use of, or reference to, the Confidential Information as demonstrated by competent business records.

 

		1.16	“CTA” means an application to a Regulatory Authority for purposes of requesting
the ability to start or continue a clinical trial.

 

		1.17	“Data Protection Law” means all applicable laws, rules and regulations, including
the United States Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (“HIPAA”),
the California Consumer Privacy Act of 2018 (“CCPA”) (to the extent applicable), and any supranational or national
legislation relating to privacy and data protection, direct marketing or the interception or communication of electronic messages,
in each case as amended, consolidated, re-enacted or replaced from time to time, including European Data Protection Laws.

 

		1.18	“Data Security Breach” shall have the meaning given in Section 13.5.

 

    	Page 3 of 73

     

    

 

		1.19	“Data Sharing Schedule” means the schedule attached hereto as Schedule I.

 

		1.20	“Data Subject” means an identified or identifiable natural person. An identifiable
natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name,
an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological,
genetic, mental, economic, cultural or social identity of that natural person.

 

		1.21	“Database Lock” means that all Sub-Study data has been received and processed,
all queries have been resolved, all external data (for example, lab results) have been integrated into the main Sub-Study database,
the completion of the final quality audit ensuring that all Sub-Study data is present, correspondent and accurate and that the
edit access of the Sub-Study database has been removed.

 

		1.22	“Debarred” or “Debarment” means that a Party or any of its
officers or directors or any other personnel (or other permitted agents of a Party hereunder) has been: (a) convicted of any of
the offenses identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector
General (OIG) website, including 42 U.S.C. 1320a-7 (http://oig.hhs.gov/exclusions/authorities.asp); (b) identified in the OIG List
of Excluded Individuals/Entities (LEIE)database (http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in
the System for Award Management (http://www.sam.gov); or (c) disqualified or proposed by FDA for disqualification from receiving
investigational products, conducting clinical studies or providing any services in any capacity to a person that has an approved
or pending drug product application or listed by any US Federal agency as being suspended, proposed for debarment, debarred, suspended,
excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a
(http://www.fda.gov/ora/compliance_ref/debar/).

 

		1.23	“Delivery” has the meaning given in Section 12.3.

 

		1.24	“Dispute” has the meaning set forth in Section 30.2.

 

		1.25	“Effective Date” has the meaning set forth in the preamble.

 

		1.26	“EMA” has the meaning set forth in the definition of Applicable Law.

 

		1.27	“EU Standard Contractual Clauses” means those standard contractual clauses issued
by the European Commission that offer sufficient safeguards on data protection for Personal Data to be transferred internationally,
which presently consist of two sets of standard contractual clauses for transfers from data controllers in the European Union to
controllers established outside the European Union or European Economic Area (Decision 2001/497/EC and Decision 2004/915/EC) and
one set of standard contractual clauses for transfers of Personal Data from controllers in the European Union to processors established
outside the European Union or European Economic Area (Decision 2010/87/EU), in each case as amended, consolidated, re-enacted or
replaced from time to time.

 

    	Page 4 of 73

     

    

 

		1.28	“European Data Protection Laws” means the General Data Protection Regulation
2016/679 (the “GDPR”), the e-Privacy Directive 2002/58/EC, the e-Privacy Regulation 2017/003 once it takes effect,
and any relevant law, statute, declaration, decree, directive, legislative enactment, order, ordinance, regulation, rule or other
binding instrument which implements, replaces, adds to, amends, extends, reconstitutes or consolidates such laws from time to time,
including the Data Protection Act 2018 of the United Kingdom, in each case as amended, consolidated, re-enacted or replaced from
time to time.

 

		1.29	“FDA” has the meaning set forth in the definition of Applicable Law.

 

		1.30	“Field” has the meaning given in Section 4.1.

 

		1.31	“Final Sub-Study Report” has the meaning given in Section 6.7.

 

		1.32	“GCP” means the Good Clinical Practices officially published by EMA, FDA and
the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
that may be in effect from time to time and are applicable to the testing of the Compounds, including the requirements set forth
at 21 CFR Parts 50, 54, 56 and 312.

 

		1.33	“Government Official” means (a) any officer or employee of a government or any
department, agency or instrumentality of a government (which includes public enterprises and entities owned or controlled by the
state); (b) any officer or employee of a public international organization such as the World Bank or United Nations; (c) any officer
or employee of a political party or any candidate for public office; (d) any person defined as a government or public official
under applicable local laws (including anti-bribery and corruption laws) and not already covered by any of the above; and/or; (e)
any person acting in an official capacity for or on behalf of any of the above, including in each case any person with close family
members who are Government Officials with the capacity, actual or perceived, to influence or take official decisions affecting
GSK business. For the purposes of this definition, “government” means all levels and subdivisions of government, i.e.
local, regional, national, administrative, legislative, executive, or judicial and royal or ruling families.

 

		1.34	“GSK” has the meaning set forth in the preamble.

 

		1.35	“GSK Background Intellectual Property” means any Intellectual Property Rights
owned or controlled by GSK or an Affiliate of GSK that (a) exist as of the Effective Date of this Agreement or (b) arise outside
of (i.e., is not made or conceived in or through) the design or performance of the Sub-Study or the use of or reliance upon the
Licensed Clinical Data or the Confidential Information solely owned or controlled by SpringWorks or the SpringWorks Compound.

 

		1.36	“GSK Background Patents” has the meaning given in Section 16.5(b).

 

		1.37	“GSK Compound” has the meaning given in the Recitals hereto.

 

		1.38	“GSK Invention” is defined in Section 16.1.

 

    	Page 5 of 73

     

    

 

		1.39	“GSK IPR” is defined in Section 16.1.

 

		1.40	“GSK Regulatory Documentation” means any Regulatory Documentation pertaining
to the GSK Compound that exists as of the Effective Date or that is created other than in connection with this Agreement.

 

		1.41	“GSK-Related Compound” is defined in Section 16.4(b).

 

		1.42	“HIPAA” has the meaning set forth in the definition of Data Protection Law.

 

		1.43	“IND” means the Investigational New Drug Application filed or to be filed with
the FDA as described in Title 21 of the U.S. Code of Federal Regulations, Part 312, and the equivalent application in the jurisdictions
outside the United States, including an “Investigational Medicinal Product Dossier” filed or to be filed with the EMA.

 

		1.44	“Intellectual Property Rights” means all patents, inventions (whether patentable
or not), discoveries, rights in confidential information, Know-How and trade secrets (and any documents containing such confidential
information, Know-How or trade secrets), trademarks and service marks, copyrights (including in computer software) (in each case
whether registered or not), registered designs, design rights, contractual waivers of moral rights, rights in databases and collections
of data, utility models and all similar property rights whether or not registered or registrable, designs, drawings, performances,
computer programs, business or brand names, rights in domain names, metatags, goodwill or the style or presentation of goods or
services and all similar property rights whether or not registered or registrable, including applications for protection, renewal
or extension of any such rights, anywhere in the world and in each case whether subsisting now or in the future.

 

		1.45	“Jointly Owned Sub-Study Invention” has the meaning set forth in Section 16.4(a).

 

		1.46	“Joint Patent” means a patent, extension, registration, supplementary protection
or certificate of the like that issues from a Joint Patent Application.

 

		1.47	“Joint Patent Application” has the meaning set forth in Section 16.4(c).

 

		1.48	“Know-How” means any proprietary invention, innovation, improvement, development,
discovery, computer program, device, trade secret, method, know-how, process, technique or the like, including manufacturing, use,
process, structural, operational and other data and information, whether or not written or otherwise fixed in any form or medium,
regardless of the media on which contained and whether or not patentable or copyrightable, that is not generally known or otherwise
in the public domain.

 

		1.49	“Liability” has the meaning set forth in Section 22.1.

 

		1.50	“Licensed Clinical Data” means all data (including raw data) and results generated
under the Sub-Study which relates to the Combination Therapy or the SpringWorks Compound as a sole compound, including any Sample
Testing Results relating to the Combination Therapy or the SpringWorks Compound as a sole Compound, but excluding any data (including
Sample Testing Results) relating to the GSK Compound alone or use of the GSK Compound in combination with any other compound in
the Field.

 

    	Page 6 of 73

     

    

 

		1.51	“Manufacture,” “Manufactured,” or “Manufacturing”
means all activities of the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage,
filling, packaging, waste disposal, labelling, leafleting, testing, quality assurance, sample retention, stability testing, release,
dispatch and supply, as applicable.

 

		1.52	“Manufacturer’s Release” or “Release” means the certification
of release of a production lot of a Compound in accordance with the Clinical Quality Agreement.

 

		1.53	“Manufacturing Site” means the facilities where a Compound is Manufactured by
or on behalf of a Party, as such Manufacturing Site may change from time to time in accordance with Section 12.6.

 

		1.54	“Material Safety Issue” means a Party’s reasonable belief that there is
an unacceptable risk for harm in humans based on: (a) pre-clinical safety data, including data from animal toxicology studies,
or (b) the observation of serious adverse events in humans after a Party’s Compound, either as a single Compound or in combination
with any other pharmaceutical agent (including the Combination Therapy), has been administered to or taken by humans.

 

		1.55	“Mechanism of Action” means the specific biological and/or chemical interaction(s)
through which a drug substance produces its pharmacological effect(s).

 

		1.56	“Non-Conformance” has the meaning given to such term in the Clinical Quality
Agreement.

 

		1.57	“Party” has the meaning set forth in the preamble.

 

		1.58	“Personal Data”, “Process”, “Processed”
and “Processing” will be construed in accordance with the GDPR to the extent applicable. In all other instances,
to the extent HIPAA applies, Personal Data means Protected Health Information subject to HIPAA.

 

		1.59	“Pharmacovigilance Agreement” means that certain pharmacovigilance agreement
entered into by the Parties pursuant to Article 10 hereof regarding safety-related activities in relation to the Compounds.

 

		1.60	“Platform Study” means the clinical study conducted or sponsored by GSK under
which one or more sub-studies (including the Sub-Study) are conducted to evaluate the combination of the GSK Compound and other
compound(s) for the treatment of multiple myeloma, other plasma cell clone disorders and B-cell malignancies. For the avoidance
of doubt, the Sub-Study investigating the Combination Therapy to be performed under this Agreement is for the treatment of relapsed
and refractory multiple myeloma.

 

		1.61	“Platform Study IND” has the meaning given in Section 6.3.

 

    	Page 7 of 73

     

    

 

		1.62	“Platform Study Protocol” means the written documentation which describes the
Platform Study and sets forth specific activities to be performed as part of the Platform Study conduct.

 

		1.63	“Protected Health Information” will be construed in accordance with HIPAA.

 

		1.64	“Regulatory Approvals” means, with respect to a Compound, any and all permissions
required to be obtained from Regulatory Authorities and any other competent authority for the development, registration, importation
and distribution of such Compound in the United States, Europe or other applicable jurisdictions.

 

		1.65	“Regulatory Authorities” has the meaning set forth in the definition of Applicable
Law.

 

		1.66	“Regulatory Documentation” means, with respect to a Party’s Compound,
all submissions to Regulatory Authorities in connection with the development of such Compound and all INDs for such Compound and
amendments thereto, including all drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse
event files, complaint files, inspection reports and manufacturing records, in each case together with all supporting documents
(including documents that include clinical data).

 

		1.67	“Related Agreements” means the Pharmacovigilance Agreement and the Clinical
Quality Agreement.

 

		1.68	“Right of Reference” means, with respect to SpringWorks, allowing the applicable
Regulatory Authority in a country to have access to relevant information (by cross-reference, incorporation by reference or otherwise)
contained in any Regulatory Documentation (and any data contained therein) filed with such Regulatory Authority with respect to
the SpringWorks Compound, only to the extent necessary for the conduct of the Sub-Study in such country.

 

		1.69	“Samples” means biological specimens collected from subjects participating in
the Sub-Study, including urine, blood and tissue samples.

 

		1.70	“Sample Testing” means the analyses that may be performed by GSK using the applicable
Samples, as permitted in accordance with this Agreement, including Bioanalytical Testing and Biomarker Testing.

 

		1.71	“Sample Testing Results” means those data and results arising from the Sample
Testing.

 

		1.72	“Specifications” means, with respect to a given Compound, the specifications
for testing, release and stability of such Compound, as set forth in the applicable Regulatory Documentation for such Compound.

 

		1.73	“SpringWorks” has the meaning set forth in the preamble.

 

		1.74	“SpringWorks Background Intellectual Property” means any Intellectual Property
Rights owned or controlled by SpringWorks or an Affiliate of SpringWorks that (a) exist at the Effective Date of this Agreement
or (b) arise outside of (i.e., is not made or conceived in or through) the design or performance of the Sub-Study or the use of
or reliance upon Licensed Clinical Data or the Confidential Information solely owned or controlled by GSK or the GSK Compound.

 

    	Page 8 of 73

     

    

 

		1.75	“SpringWorks Background Patents” has the meaning given in Section 16.5(a).

 

		1.76	“SpringWorks Compound” has the meaning given in the Recitals hereto.

 

		1.77	“SpringWorks Invention” is defined in Section 16.2.

 

		1.78	“SpringWorks IPR” is defined in Section 16.2.

 

		1.79	“SpringWorks-Related Compound” is defined in Section 16.4(b).

 

		1.80	“SpringWorks Regulatory Documentation” means any Regulatory Documentation pertaining
to the SpringWorks Compound that exists as of the Effective Date or that is created other than in connection with this Agreement.

 

		1.81	“Sub-Study” means the clinical trial investigating the Combination Therapy for
relapsed and refractory multiple myeloma to be performed under this Agreement and pursuant to the Sub-Study Protocol.

 

		1.82	“Sub-Study Completion” means the last day on which Database Lock for the Sub-Study
occurs.

 

		1.83	“Sub-Study Inventions” means all inventions and discoveries, whether or not
patentable, that are made or conceived by either Party, its Affiliates or subcontractors, in the design or performance of the Sub-Study
and/or that are made or conceived by a Party, its Affiliates or subcontractors, through use of the Licensed Clinical Data.

 

		1.84	“Sub-Study Protocol” means the written documentation agreed between the Parties
which describes the Sub-Study and sets forth specific activities to be performed as part of the Sub-Study conduct, a summary of
which is attached hereto as Appendix A.

 

		1.85	“Sub-Study Regulatory Documentation” means any Regulatory Documentation pertaining
to the Sub-Study whether created before, during or after the expiry of the term of this Agreement.

 

		1.86	“Term” has the meaning given in Section 24.1.

 

		1.87	“Third Party” means any person or entity other than GSK, SpringWorks or their
respective Affiliates.

 

		1.88	“Third Party License Payment” means any payments (e.g. upfront payments, milestones,
royalties) due to any Third Party under license agreements or other written agreements granting rights to intellectual property
owned or controlled by such Third Party to the extent that such rights are necessary for (a) the making, using or importing of
a Party’s Compound for the conduct of the Sub-Study, or (b) the conduct of the Sub-Study.

 

 

    	Page 9 of 73

     

    

 

		2.	SCOPE OF THE AGREEMENT.

 

		2.1	GSK agrees to Manufacture and supply the GSK Compound for purposes of the Sub-Study as set forth
in Article 12. SpringWorks agrees to Manufacture and supply the SpringWorks Compound for purposes of the Sub-Study as set forth
in Article 12. Without limiting the foregoing, each Party is responsible for obtaining all approvals (including facility licenses)
that are required by the applicable Regulatory Authority to Manufacture its Compound in accordance with Applicable Law (provided
that for clarity, GSK shall be responsible for obtaining Regulatory Approvals (other than the Manufacturing approvals for the SpringWorks
Compound) for the Sub-Study as set forth in Sections 6.2 and 6.3).

 

		2.2	Each Party shall have the right to delegate or subcontract any portion of its obligations hereunder
to subcontractors, provided that SpringWorks’ right to so delegate or subcontract shall extend solely to its obligation to
Manufacture the SpringWorks Compound. Each Party shall remain solely and fully liable for the performance of such subcontractors
and shall ensure that its subcontractors performs its obligations pursuant to the terms of this Agreement. Each Party shall use
reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by such subcontractors.

 

		2.3	Subject to Article 5, this Agreement does not create any obligation on the part of SpringWorks
to provide the SpringWorks Compound for any activities other than the Sub-Study, nor does it create any obligation on the part
of GSK to provide the GSK Compound for any activities other than the Sub-Study.

 

		2.4	A summary of the Sub-Study Protocol has been agreed to by the Parties as of the Effective Date
and is attached as Appendix A. GSK will further develop the Sub-Study Protocol in coordination with SpringWorks. After the Sub-Study
Protocol has been mutually agreed by the Parties, it shall be deemed a part of this Agreement. Thereafter, subject to Section 9.2,
GSK shall have the final decision-making authority regarding changes to the contents of the Sub-Study Protocol, provided that GSK
shall not amend any part of the Sub-Study Protocol if such amendment relates to the dosing of the SpringWorks Compound, the dosing
schedule for the SpringWorks Compound and/or safety measures for the SpringWorks Compound, without SpringWorks’ prior written
consent, which consent shall not be unreasonably withheld, delayed or conditioned, and provided further that (i) such consent shall
not be required for a change which does not relate to the dosing of the SpringWorks Compound, the dosing schedule for the SpringWorks
Compound and/or safety measures for the SpringWorks Compound; and (ii) GSK shall provide prompt notice (but in any event no fewer
than [***] Business Days before the sooner of the effective date of amendment or submission of the amendment to a Regulatory
Authority) of every change to the Sub-Study Protocol to SpringWorks and a copy of the amended Sub-Study Protocol and shall consider
in good faith any comments provided by SpringWorks with respect to such proposed amendment.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 10 of 73

     

    

 

		2.5	GSK shall prepare the patient informed consent form for the Sub-Study (which shall include provisions
designed to permit the lawful sharing of Samples and Licensed Clinical Data and the use of Samples in Sample Testing) in accordance
with Applicable Law and in consultation with SpringWorks and shall consider SpringWorks’ comments in good faith; provided
that SpringWorks shall provide the portion of the informed consent form relating to the SpringWorks Compound, which shall be prepared
in accordance with Applicable Law and in respect of which SpringWorks shall consult with GSK (and all comments by GSK shall be
considered by SpringWorks in good faith).

 

		3.	COSTS OF SUB-STUDY.

 

		3.1	The Parties agree:

 

		(a)	all expenses in relation to the following provisions shall be borne or shared by the Parties as
provided in the relevant Articles:

 

		(i)	Manufacturing of the GSK Compound and SpringWorks Compound, according to Article 12; and

 

		(ii)	any costs associated with Intellectual Property Rights, according to Article 16; and

 

		(b)	if the conduct of the Sub-Study requires any Third Party License Payment, the Party required to
make such payment shall be responsible for the same.

 

		3.2	Subject to Section 3.1, GSK shall bear all other costs associated with the conduct of the Sub-Study,
including the costs associated with the Regulatory Approvals for the Sub-Study (except for any costs associated with the Manufacture
by SpringWorks of the SpringWorks Compound, in respect of which SpringWorks shall be solely responsible).

 

		4.	EXCLUSIVITY.

 

		4.1	Commencing on the Effective Date and continuing until [***] ,
SpringWorks and its Affiliates shall not directly or indirectly undertake any pre-clinical or clinical studies or supply or license
the SpringWorks Compound to any Third Party in connection with any use of the SpringWorks Compound in the development or commercialization
of any combination therapy using any agent that binds to a B-cell maturation antigen (BCMA) (the “Field”) other
than in connection with the Sub-Study.

 

		5.	FOLLOW ON STUDIES.

 

		5.1	Within [***] days of the Sub-Study Completion (or at any earlier point agreed upon by the Parties),
either Party shall have the option to propose new agreement(s) for the purpose of performing one or more additional studies of
the Combination Therapy for the treatment of relapsed and refractory multiple myeloma, including phase II and phase III studies
(including registration studies) (collectively, the “Follow On Studies”). In each such case, the Parties shall
work in good faith, but will have no obligation, for up to a period of [***] days after each such proposal (such period to be extended
for one additional period of [***] days upon written notice being provided by one Party the other Party, such notice to be provided
no later than [***] days prior to expiry of the initial [***] day period), to reach agreement upon the details of such agreement(s)
and such Follow On Study(ies), including development of protocols and identification of the study sponsor and other relevant terms
(including any agreed right of reference for SpringWorks). Any agreement between the Parties for the conduct of the Follow On Study(ies)
shall be set forth in written agreement(s) executed by the Parties and shall be on substantially the same terms and conditions
as this Agreement.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 11 of 73

     

    

 

		5.2	If the Parties do not reach agreement on the terms for such Follow On Study, and one Party
                                                                                                  (“sponsoring Party”) but not the other Party (“nonparticipating Party”) wishes to
                                                                                                  proceed with any such Follow On Study, and the nonparticipating Party does not object to the protocol based on safety
                                                                                                  concerns, then the sponsoring Party may proceed with the Follow On Study. The nonparticipating Party shall use commercially
                                                                                                  reasonable efforts to [***], on reasonable [***], and the sponsoring Party shall [***] to the extent required for the [***].
                                                                                                  The Parties shall [***], provided that the nonparticipating party’s [***].

 

		5.3	Except as expressly set forth in this Article 5, GSK and SpringWorks have no obligation to renew
or to extend this Agreement to any clinical study other than the Sub-Study, and nothing in this Agreement shall require either
Party to enter into any new agreement with the other Party.

 

		6.	CONDUCT OF THE SUB-STUDY.

 

		6.1	Each Party shall act in good faith and perform and fulfil its respective activities under this
Agreement in accordance with the Sub-Study Protocol, the terms of this Agreement and Applicable Law. Notwithstanding anything to
the contrary contained herein, neither GSK nor SpringWorks shall employ or subcontract with any person or entity that is Debarred
or otherwise ineligible for government programs for the performance of the Sub-Study or any other activities under this Agreement
or the Related Agreements.

 

		6.2	GSK shall, subject to the terms of the Sub-Study Protocol, the applicable terms of this Agreement
and any Related Agreement, manage and be responsible for the conduct of the Sub-Study, including timelines and contingency planning,
compiling, amending and filing all necessary Sub-Study Regulatory Documentation with Regulatory Authorities pursuant to the terms
of this Article 6, maintaining and acting as the sponsor of record as provided in any Applicable Law, with responsibility, unless
otherwise delegated in accordance with Applicable Law, for the Sub-Study and making all required submissions to Regulatory Authorities
related thereto.

 

		6.3	GSK will be the sponsor of the Sub-Study, which shall be conducted under the IND for the Platform
Study (the “Platform Study IND”) in accordance with the Platform Study Protocol. GSK shall own the Platform
Study IND. If a Regulatory Authority requests a separate IND for the investigation of the GSK Compound with the SpringWorks Compound
for the Sub-Study, the Parties will meet and mutually agree on an approach to address such requirement. As between the Parties,
GSK shall have the sole right and authority to make and submit filings regarding the Sub-Study to the Platform Study IND.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 12 of 73

     

    

 

		6.4	As required by Applicable Law or a Regulatory Authority and otherwise upon GSK’s reasonable
request, SpringWorks shall reasonably cooperate with GSK in good faith in support of GSK’s submissions to or interactions
with Regulatory Authorities related to the Combination Therapy or the Sub-Study, including by participating in any discussions
with any such Regulatory Authority regarding matters related to the Combination Therapy or the Sub-Study.

 

		6.5	GSK shall provide to SpringWorks all Sub-Study information and documentation requested by SpringWorks
and within GSK’s possession or control as reasonably required to enable SpringWorks to comply with any of its legal and regulatory
obligations, or any request by any Regulatory Authority, related to the SpringWorks Compound.

 

		6.6	GSK shall provide to SpringWorks copies of all Licensed Clinical Data, in electronic form or other
mutually agreeable alternate form on the timelines specified in the Data Sharing Schedule or on mutually agreed timelines, provided
that GSK has obtained all necessary consents required to lawfully share such Licensed Clinical Data. GSK shall use commercially
reasonable efforts to obtain all patient authorizations and consents required under Data Protection Laws in connection with the
Sub-Study to permit such sharing of Licensed Clinical Data with SpringWorks.

 

		6.7	Without limiting the requirements of the foregoing Section 6.6, (a) within [***] Business Days
after Database Lock for the Sub-Study, GSK shall provide SpringWorks with: (i) an electronic copy of the top-line report for the
Sub-Study and (ii) an electronic first draft of the report for the Sub-Study following Sub-Study Completion in accordance with
the results and analysis plan for the Sub-Study. SpringWorks shall review such first draft report and provide comments to GSK within
[***] Business Days of the date on which it was sent by GSK, and GSK shall consider such comments in good faith; (b) if applicable,
following review of the first draft pursuant to (a), any subsequent draft reports, which SpringWorks shall review and on which
SpringWorks shall provide comments within [***] Business Days of the date on which it was sent by GSK. GSK shall consider such
comments in good faith; and (c) a final version of the report (the “Final Sub-Study Report”) no later than [***]
months following receipt of SpringWorks’ comments on (a) or (b), as applicable. GSK shall not include any statements in the
Final Sub-Study Report relating to the SpringWorks Compound which have not been approved by SpringWorks.

 

		6.8	SpringWorks will provide to GSK any data related to the SpringWorks Compound that is required for
the conduct of the Sub-Study, whether generated by preclinical or clinical studies, and any associated documentation (including
the current package insert for the SpringWorks Compound and the current investigator’s brochure for the SpringWorks Compound),
that exists and is controlled by SpringWorks at the time of the Effective Date and any such data that becomes newly available and
is controlled by SpringWorks during the Term in a timely manner, and will provide any updates thereto to GSK, in a timely manner,
as reasonably required to conduct the Sub-Study, including to meet any regulatory requirements pertaining to the conduct of the
Sub-Study, and to enable GSK to draft and update as necessary the investigator’s brochure for the Sub-Study.The foregoing
obligation shall not apply to the extent SpringWorks’ compliance therewith would constitute a breach of an agreement between
SpringWorks and any Third Party: (a) which is entered into prior to the Effective Date; or (b) which is entered into on or after
the Effective Date, provided however that: (i) SpringWorks shall use commercially reasonable efforts to include a provision
in such agreement that permits the sharing of data as set forth in this Section 6.8; and (ii) [***]; and (iii) [***]. SpringWorks
represents and warrants that to its knowledge as at the Effective Date it is not a party to an agreement with any Third Party which
would prohibit the sharing of data as set forth in this Section 6.8.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

    	Page 13 of 73

     

    

 

		7.	RIGHT OF REFERENCE

 

		7.1	SpringWorks hereby grants to GSK and its Affiliates (including the right to sublicense to the (sub)licensees
and subcontractors of the GSK Compound) a Right of Reference to the SpringWorks Regulatory Documentation (including the appropriate
INDs and CTAs) for the sole purpose of enabling GSK, its Affiliates, (sub)licensees and subcontractors to apply for and maintain
any and all Regulatory Approvals, required to conduct the Sub-Study in accordance with this Agreement. SpringWorks shall promptly
provide to GSK or its nominee and FDA or other Regulatory Authorities all letters of authorization required to enable such Right
of Reference. If SpringWorks’ CTA is not available in a given country, SpringWorks will file its CMC data with the Regulatory
Authority for such country, referencing GSK’s CTA as appropriate (however, GSK shall have no right to directly access the
CMC data).

 

		7.2	Subject to Section 16.4(b), consistent with GSK’s ownership of all Clinical Data pursuant
to Section 15.1, and without limiting the generality of the foregoing, SpringWorks acknowledges and agrees that GSK shall have
the right to use and analyze the Clinical Data in connection with the independent development, commercialization or other exploitation
of the GSK Compound (individually or in combination with other drugs and/or other pharmaceutical agents), for inclusion in the
safety database for the GSK Compound and the Combination Therapy, and/or exercise by GSK of its rights under Section 7.1, which
rights shall survive any expiration or termination of this Agreement.

 

		8.	JOINT DEVELOPMENT COMMITTEE

 

		8.1	The Parties shall form a joint development committee (the “Joint Development Committee”
or “JDC”), made up of three (3) representatives of each of SpringWorks and GSK unless otherwise agreed (but
in any event, the JDC shall be made up of an equal number of representatives from each Party), which shall have responsibility
for coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project
manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating
the exchange of information between the Parties, with respect to the Sub-Study, and shall notify the other Party in writing regarding
the name and contact details of the Project Manager promptly following the Effective Date. Other JDC members will be agreed by
the Parties promptly following the Effective Date, but no later than five (5) Business Days prior to the first JDC meeting. The
JDC shall meet for the first time after the Effective Date and prior to the Sub-Study initiation, and then no less than quarterly,
or more or less often as agreed by the JDC, to provide an update on Sub-Study progress. Five (5) Business Days prior to any such
meeting, the GSK Project Manager will provide a draft meeting agenda to the SpringWorks Project Manager for review and comment.
[***] prior to any such meeting, the GSK Project Manager shall provide: (a) a final draft of the meeting agenda (incorporating
any comments from the SpringWorks Project Manager) and (b) an update in writing to the SpringWorks Project Manager, which update
shall contain information in reasonable detail about [***]. The minutes of each JDC meeting will be drafted by the meeting’s
secretary and shall summarize discussion highlights, actions, and agreements. The draft minutes shall be circulated within three
(3) business days of the JDC meeting by the GSK Project Manager, thereafter, the GSK Project Manager shall circulate a final version
of such minutes to the JDC at least [***] Business Day in advance of the next JDC meeting. The first such secretary shall be
the GSK Project Manager and thereafter the secretarial appointment shall alternate between the SpringWorks Project Manager and
the GSK Project Manager.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 14 of 73

     

    

 

		9.	SAMPLE TESTING.

 

		9.1	GSK shall perform or have performed all Sample Testing and shall own all Samples and Sample Testing
Results. Solely to the extent specified on the Data Sharing Schedule as being shared, GSK shall provide to SpringWorks the Sample
Testing Results in electronic form or other mutually agreeable alternate form, on the timelines specified in the Data Sharing Schedule
or as otherwise mutually agreed.

 

		9.2	GSK shall perform Sample Testing of Biomarkers to the Sub-Study as set out in the Protocol as
                                                                                                  of the Effective Date and as may be agreed between the Parties during the Term of this Agreement (“Biomarker
                                                                                                  Testing”). The Parties shall discuss in good faith and may agree that GSK should [***]. GSK shall be responsible
                                                                                                  for directing and overseeing the conduct of any Biomarker Testing (including as may be mutually agreed after Effective Date).
                                                                                                  In the event that a Biomarker discovered or developed by SpringWorks may be relevant to the Sub-Study, then the Parties shall
                                                                                                  discuss and agree [***] and [***] to GSK. Any agreed Biomarker Testing
                                                                                                  (including as set out in the Protocol as of the Effective Date) shall be performed at GSK’s expense.

 

		9.3	SpringWorks shall identify to GSK in writing its preferred vendor(s) for the conduct of bioanalytical
testing relating to pharmacokinetic Samples from Sub-Study subjects as provided in the Sub-Study Protocol (the “Bioanalytical
Testing”) on or by the Effective Date. GSK shall use commercially reasonable efforts to use such preferred vendor(s)
for the Bioanalytical Testing, provided that such vendor(s) are approved in accordance with GSK’s internal due diligence
processes and acceptable to GSK’s procurement and/or third party resourcing functions, as applicable (“Approved
Vendor(s)”). [***].
The Bioanalytical Testing shall be conducted [***] and GSK shall be responsible for overseeing the conduct of
such testing by the Approved Vendor(s). SpringWorks shall: (a) provide the necessary authorization for the Approved Vendor(s) to
conduct the Bioanalytical Testing on behalf of GSK and for the delivery of the results of such testing to GSK so that the results
may be included in the Final Sub-Study Report, and (b) authorize the Approved Vendor(s) to provide GSK with access to the validation
report and method for the analysis of the SpringWorks Compound, in the case of both (a) and (b), no later than [***] days following
the Effective Date.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

    	Page 15 of 73

     

    

 

		10.	PHARMACOVIGILANCE AGREEMENT.

 

		10.1	The Parties (or their respective Affiliates) will use commercially reasonable efforts to execute
the Pharmacovigilance Agreement within [***] days of the Effective Date, but in any event no later than the date the first dose
of the SpringWorks Compound, is administered as part of the Sub-Study, to ensure the exchange of relevant safety data within appropriate
timeframes and in appropriate format to enable the Parties to fulfil local and international regulatory reporting obligations and
to facilitate appropriate safety reviews. In the event of a conflict between this Agreement and the Pharmacovigilance Agreement,
the terms of the Pharmacovigilance Agreement shall control in relation to safety issues only. The Parties acknowledge that the
execution of the Pharmacovigilance Agreement is a condition precedent to dosing of patients in the Sub-Study with the SpringWorks
Compound.

 

		11.	CLINICAL QUALITY AGREEMENT.

 

		11.1	The Parties (or their respective Affiliates) will use commercially reasonable efforts to execute
the Clinical Quality Agreement for the SpringWorks Compound within [***] days of the Effective Date, but in no event later than
the date on which the first shipment of SpringWorks Compound is shipped to GSK or its nominee for use in the Sub-Study. The Parties
acknowledge that the execution of the Clinical Quality Agreement is a condition precedent to the supply of Compound for the Sub-Study.
In the event of a conflict between the terms of this Agreement and the terms of the Clinical Quality Agreement, the terms of the
Clinical Quality Agreement shall govern in respect of technical quality issues only.

 

		12.	SUPPLY AND USE OF THE COMPOUNDS.

 

		12.1	Supply of the Compounds. GSK shall supply, or cause to be supplied, at its sole cost and
expense, cGMP-grade quantities of the GSK Compound for use in the Sub-Study, and in accordance with the terms of this Article 12.
SpringWorks shall supply, or cause to be supplied, at its sole cost and expense, cGMP-grade quantities of SpringWorks Compound
for use in the Sub-Study, in the quantities and on the timelines set forth on Appendix B, and in accordance with the terms of this
Article 12. In the event that GSK determines that the quantities of the SpringWorks Compound set forth on Appendix B are not sufficient
to complete the Sub-Study, GSK shall notify SpringWorks, and the Parties shall agree in good faith on additional quantities of
SpringWorks Compound to be provided to complete the Sub-Study and the schedule on which such additional quantities shall be provided.
Each Party shall notify the other Party promptly in the event of any Manufacturing or supply issues, including any delay in supply
of its Compound, that is reasonably likely to adversely affect the conduct or timelines of the Sub-Study as contemplated by this
Agreement. Each Party shall, within [***] days of the Effective Date, provide to the other Party the name and contact details of
a person responsible for assisting with coordinating, and facilitating the resolution of any issues or concerns arising in connection
with the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, in the
event that either Party is not supplying its Compound in accordance with the terms of this Agreement, or is allocating under Section
12.11, then the other Party shall have no obligation to supply its Compound, or may allocate proportionally. Each Party shall ensure
that all activities conducted by such Party, its Affiliates and its permitted (sub)contractors and (sub)licensees under this Article
12 are conducted in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement and applicable safety
and environmental protocols.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 16 of 73

     

    

 

		12.2	Minimum Shelf Life Requirements. Each Party shall supply its Compound hereunder with an
adequate remaining shelf life at the time of Delivery to meet the Sub-Study requirements.

 

		12.3	Delivery of Compounds.

 

		(a)	SpringWorks will deliver, at its sole cost, the SpringWorks Compound DDP (INCOTERMS 2010) to GSK’s,
or its designee’s location as specified by GSK (“Delivery” with respect to such SpringWorks Compound).
Title and risk of loss for the SpringWorks Compound shall transfer from SpringWorks to GSK at Delivery. All costs associated with
the subsequent transportation, warehousing and distribution to Sub-Study sites of SpringWorks Compound after Delivery takes place
shall be borne by GSK. For the avoidance of doubt, if prior to Delivery the SpringWorks Compound for any reason or in any way becomes
lost, damaged, destroyed or becomes unable to comply with applicable Specifications, SpringWorks shall be obligated to replace
the same at its sole cost and to use commercially reasonable efforts to do so as soon as practicable in order to cause the least
disturbance to the conduct and timelines of the Sub-Study.

 

		(b)	GSK is solely responsible, at its sole cost, for supplying (including all Manufacturing, acceptance
and release testing) the GSK Compound for the Sub-Study, and the subsequent handling, storage, transportation, warehousing and
subsequent distribution to Sub-Study sites of the GSK Compound supplied hereunder. For purposes of this Agreement, the “Delivery”
of a given quantity of the GSK Compound shall be deemed to occur when such quantity is packaged for shipment to a Sub-Study site.

 

		12.4	Labelling and Packaging; Use of SpringWorks Compound. The Parties’ obligations with
respect to the labelling and packaging of the GSK Compound and the SpringWorks Compound are as set forth in the Clinical Quality
Agreement. Notwithstanding the foregoing or anything to the contrary contained herein, SpringWorks shall supply the SpringWorks
Compound to GSK in the form of unlabelled, [***], and GSK shall be responsible for labelling and packaging such bottles for use
in the Sub-Study. For the avoidance of doubt, GSK shall use such SpringWorks Compound solely to perform the Sub-Study and for no
other purpose.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 17 of 73

     

    

 

		12.5	Product Specifications. A certificate of analysis, and such other documentation as may be
agreed to by the Parties and set forth in the Clinical Quality Agreement, shall accompany each shipment of the SpringWorks Compound
to GSK in accordance with the terms of the Clinical Quality Agreement. SpringWorks shall be responsible for any failure of the
SpringWorks Compound to meet the Specifications and shall replace any such SpringWorks Compound free of charge; provided that,
to the extent that such failure is caused by GSK’s negligence or intentional misconduct in the shipping, storage or handling
conditions after Delivery to GSK hereunder, GSK shall pay the actual cost of such replacement SpringWorks Compound without markup.
Upon written request, GSK shall provide SpringWorks with a certificate of analysis covering each shipment of GSK Compound used
in the Sub-Study.

 

		12.6	Changes to Manufacturing. Each Party may make changes from time to time to its Compound
or the Manufacturing Site in accordance with the Clinical Quality Agreement; provided that the intended changes would not require
a submission, amendment or variation to the Platform Study IND or the Sub-Study, and provided further that the Party making such
change provides the other Party with prior written notice of the intended changes. In the case of proposed changes to the Compound
or the Manufacturing Site which would require a submission, amendment or variation to the Platform Study IND or the Sub-Study,
the Party proposing such change shall provide prior written notice to the other Party of such intended changes, providing reasonable
detail, and the Party receiving such notice shall consider such request in good faith.

 

		12.7	Product Testing; Noncompliance. After Manufacturer’s Release of the SpringWorks Compound
but prior to shipment to GSK, SpringWorks shall provide GSK with such certificates and documentation as described in the Clinical
Quality Agreement. GSK shall, within the time defined in the Clinical Quality Agreement, perform (a) with respect to the SpringWorks
Compound, the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement, and (b) with respect
to the GSK Compound, the testing and release procedures allocated to it under the Clinical Quality Agreement.

 

		12.8	Non-Conformance.

 

		(a)	In the event that either Party becomes aware that any Compounds may have a Non-Conformance, despite
any testing and quality assurance activities (including any activities conducted by the Parties under Section 12.7 (After Manufacturer’s
Release)), such Party shall immediately notify the other Party in accordance with the procedures of the Clinical Quality Agreement.
The Parties shall investigate any Non-Conformance in accordance with Section 12.10 (Investigations) and any discrepancy between
them shall be resolved in accordance with Section 12.9 (Resolution of Discrepancies).

 

    	Page 18 of 73

     

    

 

		(b)	In the event any proposed or actual shipment of the SpringWorks Compound (or portion thereof) shall
be agreed to have a Non-Conformance at the time of Delivery to GSK, then unless otherwise agreed to by the Parties, SpringWorks
shall replace such SpringWorks Compound as is found to have a Non-Conformance. Unless otherwise agreed to by the Parties in writing,
the sole and exclusive remedies of GSK with respect to any SpringWorks Compound that is found to have a Non-Conformance at the
time of Delivery shall be (i) replacement of such SpringWorks Compound as set forth in this Section 12.8(b), and (ii) indemnification
under Article 22 (to the extent applicable) and (iii) termination of this Agreement pursuant to Section 24.2 (to the extent applicable,
but subject to the applicable cure periods set forth therein), provided that, for clarity, GSK shall not be deemed to be waiving
any of its rights to recall Compounds in accordance with the Clinical Quality Agreement. In the event that SpringWorks Compound
is lost or damaged by GSK after Delivery, SpringWorks shall provide additional SpringWorks Compound (if available for the Sub-Study)
to GSK; provided that GSK shall reimburse SpringWorks for the actual cost of such replaced SpringWorks Compound without markup.

 

		(c)	GSK shall be responsible for, and SpringWorks shall have no obligations or liability with respect
to, any GSK Compound supplied hereunder that is found to have a Non-Conformance. GSK shall replace any GSK Compound as is found
to have a Non-Conformance. Unless otherwise agreed to by the Parties in writing, the sole and exclusive remedies of SpringWorks
with respect to any GSK Compound that is found to have a Non-Conformance at the time of Delivery shall be (i) replacement of such
GSK Compound as set forth in this Section 12.8(c) and (ii) indemnification under Article 22 (to the extent applicable).

 

		12.9	Resolution of Discrepancies. If SpringWorks disagrees with any determination of Non-Conformance
by GSK, such dispute shall be escalated to SpringWorks’ Head of CMC and GSK’s Director of Quality External Supply,
North America, or such other persons as they may designate in writing. If such quality representatives cannot reach a resolution
to the discrepancy, they shall escalate it to the head of quality of each Party for resolution. If each Party’s head of quality
cannot reach a resolution, the dispute resolution procedure set out at Article 30 shall apply.

 

		12.10	Investigations. The process for investigations of any Non-Conformance shall be handled in
accordance with the provisions set forth in the Clinical Quality Agreement.

 

		12.11	Shortage; Allocation. Without limiting its other obligations hereunder, in the event of
a shortage of a Compound such that a Party reasonably believes that it will not be able to fulfil its supply obligations hereunder
with respect to the Compound it is supplying, such Party will provide prompt written notice to the other Party thereof (including
the reason for the shortage and the quantity of such Compound that such Party reasonably determines it will be able to supply)
and, upon request, the Parties will promptly discuss such situation in good faith (including how the quantities of Compound that
such Party is able to supply hereunder will be allocated within the Sub-Study).

 

		12.12	Regulatory Responsibility.The responsibilities of the Parties with respect to communication
and filings with Regulatory Authorities related to the Compounds supplied hereunder in connection with the Sub-Study will be as
set forth in this Agreement, the Pharmacovigilance Agreement and the Clinical Quality Agreement entered into by the Parties or
their Affiliates in connection herewith.

 

    	Page 19 of 73

     

    

 

		12.13	Records; Audit and Inspection Rights. GSK and SpringWorks will each keep complete and accurate
records pertaining to the Manufacture, use and disposition, as applicable, of the relevant Compounds under this Agreement (in the
case of GSK, comprising the GSK Compound and, after Delivery, the SpringWorks Compound, and in the case of SpringWorks, the SpringWorks
Compound prior to Delivery (including storage, shipping (cold chain) and chain of custody activities)). Any records relating to
the quality of the Compounds shall be kept in accordance with the terms of the Clinical Quality Agreement. Without limiting the
rights of audit included within the Clinical Quality Agreement, upon the reasonable request of the other Party, each Party will
make such records open to review by such other Party for the purpose of conducting investigations for the determination of Compound
safety and/or efficacy and compliance with this Agreement with respect to the relevant Compound or as required by Applicable Laws;
provided that (to the extent permitted by Applicable Laws) the auditing Party provides written notice setting out the reason for
the audit no less than twenty (20) days in advance and any such review or audit is performed during business hours on a Business
Day in the country where the audit takes place and with minimum disruption to the day-to-day activities of the audited Party.

 

		12.14	Quality Control. GSK shall implement and perform operating procedures and controls for sampling,
stability and other testing of the GSK Compound, and for validation, documentation and release of the GSK Compound and such other
quality assurance and quality control procedures as are required by the Specifications, cGMPs and the Clinical Quality Agreement.
SpringWorks shall implement and perform operating procedures and controls for sampling, stability and other testing of the SpringWorks
Compound, and for validation, documentation and release of the SpringWorks Compound and such other quality assurance and quality
control procedures as are required by the Specifications, cGMPs and the Clinical Quality Agreement.

 

		12.15	Recalls. Recalls of the Compounds shall be governed by the terms of the Clinical Quality
Agreement.

 

		12.16	VAT.

 

		(a)	It is understood and agreed between the Parties that any payments made and any other consideration
given under this Agreement are each exclusive of any value added or similar tax (“VAT”), which shall be added
thereon as applicable and at the relevant rate. Subject to Section 12.16(b), where VAT is properly charged by the supplying Party
and added to a payment made or other consideration provided (as applicable) under this Agreement, the Party making the payment
or providing the other consideration (as applicable) will pay the amount of VAT properly chargeable only on receipt of a valid
tax invoice from the supplying Party issued in accordance with the laws and regulations of the country in which the VAT is chargeable.
Each Party agrees that it shall provide to the other Party any information and copies of any documents within its control to the
extent reasonably requested by the other Party for the purposes of (i) determining the amount of VAT chargeable on any supply made
under this Agreement, (ii) establishing the place of supply for VAT purposes, or (iii) complying with its VAT reporting or accounting
obligations.

 

    	Page 20 of 73

     

    

 

		(b)	Where one Party or its Affiliate (the “First Party”) is treated as making supply
of goods or services in a particular jurisdiction (for VAT purposes) for non-cash consideration, and the other Party or its Affiliate
(the “Second Party”) is treated as receiving such supply in the same jurisdiction, thus resulting in an amount
of VAT being properly chargeable on such supply, the Second Party shall only be obliged to pay to the First Party the amount of
VAT properly chargeable on such supply (and no other amount). The Second Party shall pay such VAT to the First Party on receipt
of a valid VAT invoice from the First Party (issued in accordance with the laws and regulations of the jurisdiction in which the
VAT is properly chargeable). The Parties agree to (i) use their reasonable endeavors to determine and agree the value of the supply
that has been made and, as a result, the corresponding amount of VAT that is properly chargeable, and (ii) provide to each other
any information or copies of documents in their control as are reasonably necessary to evidence that such supply will take, or
has taken, place in the same jurisdiction (for VAT purposes).

 

		13.	CONFIDENTIALITY.

 

		13.1	GSK and SpringWorks each agree to hold in confidence any Confidential Information of the other
Party, and neither Party shall use Confidential Information of the other Party except to fulfil such Party’s obligations
or to exercise its rights under this Agreement. For the avoidance of doubt, for the purposes of this Agreement, regardless of which
Party discloses such Confidential Information to the other, (a) all GSK IPR and GSK Regulatory Documentation shall be Confidential
Information of GSK and SpringWorks shall be deemed the receiving Party; (b) all SpringWorks IPR and SpringWorks Regulatory Documentation
shall be Confidential Information of SpringWorks and GSK shall be deemed the receiving Party; and (c) (x) Licensed Clinical Data
shall be treated as Confidential Information of both Parties and (y) all Clinical Data that is not Licensed Clinical Data shall
be the Confidential Information of GSK, and in each case such Confidential Information shall not be disclosed by the other Party
except as permitted by the terms of this Agreement or if required to be filed with or disclosed to a Regulatory Authority or included
in a product’s label or package insert. Notwithstanding the foregoing, (a) Jointly Owned Sub-Study Inventions that constitute
Confidential Information shall constitute the Confidential Information of both Parties and each Party shall have the right to use
such Confidential Information consistent with this Article 13 and Articles 16 and 17 and (b) Sub-Study Inventions that constitute
Confidential Information and that are solely owned by one Party shall constitute the Confidential Information of that Party and
each Party shall have the right to use and disclose such Confidential Information consistent with this Article 13 and Articles
16 and 17.

 

    	Page 21 of 73

     

    

 

		13.2	Neither Party shall, without the prior written permission of the other Party, nor shall permit
any of its employees, consultants, agents, permitted (sub)licensees and (sub)contractors (“Representatives”)
to, disclose any Confidential Information of the other Party to any Third Party except to the extent disclosure is (a) required
by Applicable Law, to prosecute or defend litigation or to comply with the rules or regulations of any securities exchange on which
such Party’s stock is listed; (b) required in order to fulfil the receiving Party’s obligations under this Agreement
or exercising the receiving Party’s rights to use and disclose such Confidential Information as expressly provided for in
this Agreement and solely on a need-to-know basis; (c) necessary for the conduct of the Sub-Study and solely on a need-to-know
basis; or (d) necessary for filing or prosecuting Joint Patent Applications and/or Joint Patents as permitted pursuant to Article
16; provided that, in the event of (a) above, the disclosing Party shall provide reasonable advance notice to the other Party before
making such disclosure (to the extent permitted by Applicable Law) and endeavors in good faith to secure confidential treatment
of such Confidential Information and/or reasonably assist the Party that owns such Confidential Information in seeking a protective
order or other confidential treatment, and in the event of each of (b) and (c) above, any Representative or Third Party to whom
such Confidential Information is disclosed is bound by obligations of confidentiality and non-use at least as stringent as those
set forth in this Agreement and the receiving Party remains liable for the compliance of such parties with such obligations.

 

		13.3	Each receiving Party acknowledges that in connection with its and its Representatives’ or
any Third Party’s examination of the Confidential Information of the disclosing Party, the receiving Party and its Representatives
and relevant Third Parties may have access to material, non-public information, and that the receiving Party is aware, and will
advise its Representatives and Third Parties who are informed as to the matters that are the subject of this Agreement, that securities
laws may impose restrictions on the dissemination of such information and trading in securities when in possession of such information.

 

		13.4	Notwithstanding any other provision of this Agreement GSK may, without SpringWorks’ consent,
disclose Confidential Information to Affiliates, permitted (sub)licensees, contractors, IRBs, CROs, academic institutions, consultants,
agents, and employees and contractors engaged by study sites and clinical trial investigators performing the Sub-Study, the data
safety monitoring and advisory board relating to the Sub-Study, and Regulatory Authorities or other health authorities working
with GSK on the Sub-Study, necessary for the Sub-Study, in each case solely to the extent necessary for the performance of the
Sub-Study and provided such persons (other than governmental entities) are bound by an obligation of confidentiality and non-use
at least as stringent as the obligations contained herein.

 

		13.5	When
transferring data, results and Confidential Information, all communications between GSK and SpringWorks will use encryption methods
agreed to by the Parties. Upon discovering any suspected or actual unauthorized disclosure, loss or theft of Confidential Information
or the results (a “Data Security Breach”), SpringWorks will send an e-mail to [***] notifying GSK, and upon
discovering any suspected or actual Data Security Breach, GSK will send an e-mail to [***], notifying SpringWorks. The Parties
shall work with each other in good faith to identify a root cause and remediate the Data Security Breach.

 

		14.	DATA PROTECTION.

 

		14.1	Disclosing Party Obligations. To the extent a Party (the “Disclosing Party”)
discloses, transfers or otherwise makes available any Personal Data to the other Party (the “Receiving Party”)
in connection with this Agreement, the Disclosing Party:

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 22 of 73

     

    

 

		(a)	shall, notwithstanding any other provision of this Agreement, use commercially reasonable efforts
to: (i) ensure that the Personal Data cannot be used by the Receiving Party to identify a Data Subject and (ii) not provide the
Receiving Party with any additional information (if any), including any key codes or any other mechanism or data, that may enable
the Receiving Party to attribute the Personal Data to any identifiable Data Subjects;

 

		(b)	has, to the best of its knowledge, complied with all applicable Data Protection Laws from time
to time relating to the processing of the Personal Data; and

 

		(c)	in the event that the Receiving Party receives a request from a Regulatory Authority in relation
to any Personal Data transferred to the Receiving Party by the Disclosing Party, agrees to provide reasonable assistance to the
Receiving Party to enable it to respond to the Regulatory Authority’s request which may involve contacting any clinical sites,
investigators or other subcontractors of the Disclosing Party and providing additional information, with any and all reasonable
costs incurred by the Disclosing Party arising from such support to be borne by the Receiving Party.

 

		14.2	Independent Data Controllers. To the extent applicable, the Receiving Party and the Disclosing
Party agree that (to the extent that any Personal Data is disclosed to the Receiving Party), for the purposes of Data Protection
Law, each of the Receiving Party and the Disclosing Party is an independent data controller.

 

		14.3	Fair Processing Notices. The Receiving Party further agrees that the Disclosing Party (to
the extent that any Personal Data is disclosed to the Receiving Party) may delay the disclosure of specific Personal Data to the
Receiving Party until the Disclosing Party has provided such additional fair processing information to Data Subjects in relation
to the Receiving Party’s processing of such Personal Data or taken such other actions as the Disclosing Party reasonably
believes to be required by Data Protection Law to enable the Disclosing Party to comply with its obligations thereunder. If a Party
reasonably believes that additional fair processing information or actions are required to ensure either Party’s compliance
with Data Protection Law from time to time, such Party shall notify the other Party and the Parties shall discuss in good faith
what action, if any, is required to be taken provided that the Receiving Party agrees that, as between the Parties, the Disclosing
Party shall have the sole right (but not the obligation) to communicate or procure the communication of fair processing information
(including updating such fair processing information during the term of this Agreement) to Data Subjects, in a manner and form
to be reasonably determined by the Disclosing Party in accordance with Data Protection Law, with any and all reasonable costs incurred
by the Disclosing Party arising from such support to be borne by the Receiving Party.

 

		14.4	Personal Data Transfers. Other than to countries approved, from time to time, as having
equivalent protection for Personal Data as under European Data Protection Laws by the EC, the Receiving Party shall not process
such Personal Data outside the EEA unless the Receiving Party complies with the data importer’s obligations set out in the
EU Standard Contractual Clauses for transfers from data controllers in the European Union or European Economic Area, to the extent
applicable to controllers established outside the European Union or European Economic Area pursuant to EU Commission Decision 2004/915/EC
(as amended or replaced from time to time) (the “Controller to Controller Clauses”) which are hereby incorporated
into and form part of this Agreement (and for the purposes of Annex B of such Controller to Controller Clauses, the Data Subjects,
purpose of transfer, categories of data, recipients and categories of sensitive personal data shall be as set out in Sections 14.5
to 14.10 below).

 

    	Page 23 of 73

     

    

 

		14.5	Nature and Purpose of Sharing. The Personal Data is shared, on a controller to controller
basis, solely for the purpose of conducting the Study in accordance with the terms of this Agreement and Applicable Laws, including
the manufacture and supply of each Compound, and the development, administration and registration of the Combination Therapy. The
sharing of the Personal Data is necessary for the purpose of the legitimate interests pursued by the Parties in conducting the
Study and developing the Combination Therapy as contemplated by this Agreement.

 

		14.6	Categories of Recipients. The Personal Data may only be onward transferred by the Receiving
Party as permitted by and on the terms of this Agreement.

 

		14.7	Duration of Sharing. As set out in this Agreement.

 

		14.8	Types of Personal Data Shared. The Personal Data will include:

 

		(a)	identification information, such as name, address, contact information and qualifications, relating
to each Party’s personnel and those working on such Party’s behalf in connection with the conduct of the Study and
the development of the Combination Therapy by the Parties in connection with this Agreement;

 

		(b)	identification information, such as name, address and contact information, relating to each subject
participating in the Study, in addition to; and

 

		(c)	identification information, such as name, address, contact information and qualifications on healthcare
professionals and investigators involved in the Study.

 

		14.9	Special Category Personal Data Shared. The Personal Data will include any special categories
of Personal Data, including medical records, ethnic or racial background, test results, results of physical examinations, samples,
adverse effects and any other health information.

 

		14.10	Categories of Data Subjects. The Personal Data will relate to Data Subjects including: (i)
each Party’s personnel and those working on such Party’s behalf in connection with the Study; (ii) healthcare professionals
and investigators involved in the Study; (iii) Study subjects and patients; and (iv) end users of the Compounds.

 

		14.11	Data Minimization. Each Party acknowledges that each Party is under an obligation to ensure
that the Personal Data they process and which the Disclosing Party discloses is limited to only that which is necessary for the
purposes of the processing, therefore the Disclosing Party shall (to the extent that any Personal Data is disclosed to the Receiving
Party), notwithstanding any other provision of this Agreement, use commercially reasonable efforts to transfer only that Personal
Data which is required to facilitate the performance of this Agreement. If the Receiving Party reasonably believes that additional
Personal Data is required to be disclosed to enable the performance of this Agreement, the Receiving Party shall notify the Disclosing
Party and the Parties shall discuss in good faith whether such additional Personal Data will be disclosed by the Disclosing Party,
taking into account the Disclosing Party’s obligations under applicable European Data Protection Laws, the potential for
the provision of anonymized data in place of the requested Personal Data, and any actions which are required to be taken by either
Party in connection with such requested disclosure.

 

    	Page 24 of 73

     

    

 

		14.12	Receiving Party Obligations. The Receiving Party shall, and shall cause its officers, employees,
agents, attorneys, consultants, advisors and other representatives to:

 

		(a)	process any Personal Data in accordance with Data Protection Law and solely for the purposes disclosed
and purposes compatible under applicable Data Protection Law with the purposes disclosed to the relevant Data Subjects from time
to time or as otherwise permitted by applicable Data Protection Law;

 

		(b)	implement appropriate technical and organizational measures to ensure a level of security appropriate
to the risk, taking into account the state of the art, the costs of implementation and the nature, scope, context and purpose of
processing and promptly notify the Disclosing Party if any Personal Data is subject to any unauthorized or unlawful access, loss,
destruction or damage; and

 

		(c)	not further disclose the Personal Data to any Third Party (including, for clarity, any subcontractors)
in a manner incompatible with the fair processing information provided to the relevant Data Subjects.

 

		14.13	Data Subject Requests. In the event that either Party directly receives a request from a
Data Subject for the rectification or erasure of such Personal Data (or any other request regarding Data Subjects exercising rights
under any applicable European Data Protection Law) (a “Data Subject Request”), the Party receiving the request
shall where appropriate pass on the details of the request to the other Party; and each Party shall provide the other any reasonable
assistance as is required for the purposes of responding to the Data Subject Request in accordance with any applicable European
Data Protection Law, which may involve contacting clinical sites, investigators or other subcontractors of the disclosing Party
and providing additional information.

 

		14.14	CCPA. To the extent that the CCPA is applicable to either Party: (i) such Party agrees to
comply with all of its obligations under the CCPA; and (ii) in relation to any communication of “personal information”
(as defined by the CCPA) from one Party to the other Party pursuant to this Agreement, the Parties agree that no monetary or other
valuable consideration is being provided for such personal information and therefore neither Party is “selling” (as
defined by the CCPA) personal information to the other Party.

 

		15.	CLINICAL DATA OWNERSHIP & USE.

 

		15.1	[***].

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 25 of 73

     

    

 

		15.2	SpringWorks hereby assigns, and shall cause its Affiliates to so assign, to GSK, without additional
compensation, such right, title and interest in and to any Clinical Data as is necessary to fully effect the ownership described
in Section 15.1, and agrees to execute all instruments as may be reasonably necessary to effect the same.

 

		15.3	Subject to Section 16.4(b), GSK hereby grants, and shall cause its Affiliates to so grant, to SpringWorks
the right to use and disclose the Licensed Clinical Data for: (a) the development of the Combination Therapy; (b) to seek approval
for or a change or expansion of the label indications for the SpringWorks Compound (individually or in combination with other drugs
and/or pharmaceutical agents); (c) subject to Section 4.1, the development, commercialization or other exploitation of the SpringWorks
Compound (individually or in combination with other drugs and/or pharmaceutical agents); (d) seeking regulatory approval for use
of the SpringWorks Compound (individually or in combination with other drugs and/or pharmaceutical agents); and (e) filing, prosecuting,
and enforcing patent applications and patents in accordance with Article 16; provided, however, that the foregoing shall not limit
or restrict SpringWorks’ ability to (x) use or disclose the Licensed Clinical Data as may be necessary to comply with Applicable
Laws, including as required to respond to regulatory queries, or with SpringWorks’ internal policies and procedures with
respect to pharmacovigilance and adverse event reporting; or (y) share with Third Parties or Affiliates safety data where, due
to severity, frequency or lack of reversibility, SpringWorks needs to use such safety data with respect to the SpringWorks Compound
or the Combination Therapy to ensure patient safety.

 

		16.	INTELLECTUAL PROPERTY.

 

		16.1	Inventions Owned by GSK. The Parties agree that all rights to (a) GSK Background Intellectual
Property and (b) Sub-Study Inventions solely relating to (i) the GSK Compound or (ii) GSK-Related Compound, are in each case the
exclusive property of or shall be exclusively controlled by GSK (each such invention described in (i) and (ii) a “GSK
Invention”, and together with the GSK Background Intellectual Property, the “GSK IPR”). As between
the Parties, GSK shall be entitled to file in its own name relevant patent applications and to own resultant patent rights for
all GSK Background Intellectual Property and GSK Inventions. For the avoidance of doubt, any invention generically encompassing
a GSK Compound (and not any SpringWorks proprietary compound including the SpringWorks Compound or SpringWorks-Related Compound)
within its scope, even where such GSK Compound is not disclosed per se (each a “GSK-Related Invention”), is
the exclusive property of GSK. For the avoidance of doubt, and subject to Article 15, any Intellectual Property Rights relating
to Clinical Data shall be the exclusive property of or shall be exclusively controlled by GSK, [***].

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 26 of 73

     

    

 

		16.2	Inventions Owned by SpringWorks. The Parties agree that all rights to (a) SpringWorks Background
Intellectual Property and (b) Sub-Study Inventions relating to (i) the SpringWorks Compound or (ii) a SpringWorks-Related
Compound, are in each case the exclusive property of SpringWorks (each such invention described in (i) and (ii) a “SpringWorks
Invention”, and together with the SpringWorks Background Intellectual Property, the “SpringWorks IPR”).
As between the Parties, SpringWorks shall be entitled to file in its own name relevant patent applications and to own resultant
patent rights for all SpringWorks Background Intellectual Property and SpringWorks Inventions. For the avoidance of doubt, any
invention generically encompassing a SpringWorks Compound (and not any GSK proprietary compound including the GSK Compound or GSK-Related
Compound) within its scope, even where such SpringWorks Compound is not disclosed per se (each a “SpringWorks-Related
Invention”), is the exclusive property of SpringWorks.

 

		16.3	Each Party hereby assigns, and shall cause its Affiliates to so assign, to the other Party, without
additional compensation, such right, title and interest in and to any Sub-Study Inventions as is necessary to fully effect the
ownership described in Sections 16.1 and 16.2, and agrees to execute all instruments as may be reasonably necessary to effect the
same.

 

		16.4	Joint Ownership and Prosecution.

 

		(a)	Subject to Sections 16.1, 16.2 and 16.5, all rights to all Sub-Study Inventions relating to,
                                                                                                      or covering, [***] (GSI) (a “Jointly Owned Sub-Study Invention”) shall be owned jointly by GSK and
                                                                                                      SpringWorks. Each Party hereby assigns to the other Party a one-half, undivided interest under its right, title and interest
                                                                                                      in, to and under Jointly Owned Sub-Study Inventions. GSK and SpringWorks shall each be entitled to exploit the Jointly Owned
                                                                                                      Sub-Study Inventions solely in accordance with this Section 16.4, and without accounting or financial payment to the other
                                                                                                      Party and without the consent of the other Party. For those countries where a specific license is required for a joint owner
                                                                                                      of a Jointly Owned Sub-Study Invention to practice such Jointly Owned Sub-Study Invention in such countries, (i) SpringWorks
                                                                                                      hereby grants to GSK a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license under
                                                                                                      SpringWorks’ right, title and interest in and to all Jointly Owned Sub-Study Inventions to use such Sub-Study
                                                                                                      Inventions subject to and in accordance with the terms and conditions of this Agreement (including Section 16.4(b)), and (ii)
                                                                                                      GSK hereby grants to SpringWorks a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license
                                                                                                      under GSK’s right, title and interest in and to all Jointly Owned Sub-Study Inventions to use such Sub-Study Inventions
                                                                                                      in accordance with the terms and conditions of this Agreement (including Section 16.4(b)). For the avoidance of doubt, the
                                                                                                      terms of this Agreement do not provide GSK or SpringWorks with any rights, title or interest to or in or any license to the
                                                                                                      other Party’s background Intellectual Property Rights except as necessary to conduct the Sub-Study and as expressly set
                                                                                                      forth in this Article 16.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 27 of 73

     

    

 

		(b)	Each Party shall have the right to freely exploit each Jointly Owned Sub-Study Invention and the
Licensed Clinical Data, both within and outside the scope of the Sub-Study, without accounting to or any other obligation to the
other Party; provided, however, that (A) SpringWorks may not exploit the Jointly Owned Sub-Study Invention nor the Licensed Clinical
Data, directly or indirectly, to research, develop or commercialize (i) a compound [***] (each such compound a “GSK-Related
Compound”) or (ii) [***], and (B) GSK may not exploit the Jointly Owned Sub-Study Invention nor the Licensed Clinical
Data, directly or indirectly, to research, develop or commercialize (i) a compound [***] (each such compound a “SpringWorks-Related
Compound”) or (ii) [***]. Notwithstanding the foregoing, each Party shall have the right to practice each Jointly Owned
Sub-Study Invention and the right to use the Licensed Clinical Data in performing its obligations and exercising its rights under
this Agreement. For clarity, nothing in this Section 16.4(b) shall restrict or prevent GSK or SpringWorks from directly or indirectly,
researching, developing or commercializing a GSK-Related Compound or SpringWorks-Related Compound, without the use of the
Jointly Owned Sub-Study Inventions or the Licensed Clinical Data.

 

		(c)	Promptly following the Effective Date, but in any event as soon as practicable after the discovery
of a Jointly Owned Sub-Study Invention, patent representatives of each of the Parties shall meet (in person or by telephone) to
discuss the patenting strategy for any Jointly Owned Sub-Study Inventions which may arise. In particular, the Parties shall
discuss which Party will file a patent application (including any provisional, substitution, divisional, continuation, continuation
in part, reissue, renewal, re-examination, extension, supplementary protection certificate and the like) in respect of any Jointly
Owned Sub-Study Invention (each, a “Joint Patent Application”), and whether the Parties wish to appoint patent
counsel that is mutually acceptable to both Parties, and in which territories such patent applications will be filed. In any event,
the Parties shall consult and reasonably cooperate with one another in the preparation, filing, prosecution (including prosecution
strategy) and maintenance of such patent application; provided, however, that GSK shall have final say in patenting strategy, and
prosecution, of any Joint Patent Application. Costs of filing, prosecuting, and maintaining Joint Patent Applications and resulting
patents and any associated expenses shall be divided equally by the Parties (50/50). Neither Party will be obligated for costs,
or any portion thereof, for filing, prosecuting, and maintaining Joint Patent Applications and Joint Patents in other jurisdictions
without prior agreement by the Parties; provided, however, that in the event that a Party does not agree to share equally the costs
for filing, prosecuting, and maintaining a Joint Patent Application in a particular jurisdiction, such Party shall not have any
rights to (i) enforce any patents arising from such Joint Patent Application in such jurisdiction (other than in connection with
Section 16.4(d)) or (ii) share in any revenues received by the other Party from the enforcement (except for reimbursement of reasonable
out-of-pocket costs, including attorneys’ fees, incurred by such Party in connection with Section 16.4(d)) or license of
any such patents or Joint Patent Application. In the event that one Party (the “Filing Party”) wishes to file
a patent application for a Jointly Owned Sub-Study Invention and the other Party (the “Non-Filing Party”) does
not want to file a patent application for such Jointly Owned Sub-Study Invention or does not want to file in a particular country,
the Non-Filing Party shall assign its undivided half-interest in such Jointly Owned Sub-Study Invention to the Filing Party and
shall execute in a timely manner and at the Filing Party’s reasonable expense a power of attorney and any additional documents
(in such country or all countries, as applicable) as may be reasonably necessary to give effect to the assignment and allow the
Filing Party to file and prosecute such patent application, and the Non-Filing Party shall cease to have payment obligations or
any rights in relation thereto. If a Party (the “Opting- out Party”) wishes to discontinue the prosecution and
maintenance of a Joint Patent Application or Joint Patent (in one or more countries), the other Party, at its sole option (the
“Continuing Party”), may continue such prosecution and maintenance. In such event, the Opting-out Party shall
assign its undivided half-interest in such Joint Patent Application and any Joint Patents issuing therefrom to the Continuing Party,
and execute in a timely manner and at the Continuing Party’s reasonable expense a power of attorney and any additional documents
(in such country or all countries, as applicable) as may be necessary to give effect to the assignment and allow the Continuing
Party to prosecute and maintain such Joint Patent Application or Joint Patent, and the Opting-Out Party shall cease to have payment
obligations or any rights in relation thereto.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 28 of 73

     

    

 

		(d)	GSK shall have the first right to initiate legal action to enforce all Joint Patents against infringement
by any Third Party where such infringement results from the development, promotion or sale of a GSK-Related Compound, but not a
SpringWorks-Related Compound, or to defend any declaratory judgment action relating thereto, at its sole expense. In the
event that GSK fails to initiate or defend such action within [***] days after being first notified of such infringement, or [***]
days before the expiration for filing such action or responding, whichever comes first, SpringWorks shall have the right to do
so at its sole expense. Similarly, SpringWorks shall have the first right to initiate legal action to enforce all Joint Patents
against infringement or misappropriation by any Third Party where such infringement results from the development, promotion or
sale of a SpringWorks-Related Compound, but not a GSK-Related Compound, or to defend any declaratory judgment action relating
thereto, at its sole expense. In the event that SpringWorks fails to initiate or defend such action within [***] days after being
first notified of such infringement, or [***] days before the expiration for filing such action or responding, whichever comes
first, GSK shall have the right to do so at its sole expense. With respect to any infringement resulting from the development,
promotion or sale of the Compounds together or any combination of a GSK-Related Compound and a SpringWorks-Related Compound, the
Parties shall agree on terms pursuant to which the Parties shall (i) coordinate legal action to enforce all Joint Patents against
such infringement and any settlement thereto, (ii) defend any declaratory judgment action relating thereto, and (iii) determine
the allocation of the costs and expenses of such litigation.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

    	Page 29 of 73

     

    

 

		(e)	If one Party brings any prosecution or enforcement action or proceeding against a Third Party with
respect to any Joint Patent, the second Party agrees to be joined as a party plaintiff where necessary and to give the first Party
reasonable assistance and authority to file and prosecute the suit. The costs and expenses of the Party bringing suit under this
Section 16.4(e) shall be borne by such Party, and any damages or other monetary awards recovered shall be shared as follows: (i)
the amount of such recovery actually received by the Party controlling such action shall be first applied to the out-of-pocket
costs of each Party in connection with such action; and then (ii) any remaining proceeds shall be shared by the Parties in proportion
based on their relative contributions to the total costs and expenses of the litigation, including any costs and expenses of a
Party to enforce any solely- owned patents. A settlement or consent judgment or other voluntary final disposition of a suit under
this Section 16.4(e) may not be entered into without the consent of the Party not bringing the suit (such consent not to be unreasonably
withheld or delayed). Furthermore, the Party not bringing the suit shall not offer the defendant in such suit any license under
the Joint Patent(s) without the consent of the Party bringing the suit.

 

		16.5	Mutual Freedom to Operate.

 

		(a)	SpringWorks hereby grants to GSK a perpetual, irrevocable, non-exclusive, worldwide,
                                                                                                      royalty-free, fully paid-up license to (i) any patent owned or controlled by SpringWorks which (A) has a priority claim that
                                                                                                      is earlier than the initiation of the Sub-Study (i.e., first dosing of the first patient in the Sub-Study) and (B)
                                                                                                      specifically claims or covers the Combination Therapy (“SpringWorks Background Patents”) and (ii) [***] each
                                                                                                      in order to practice such Combination Therapy for all purposes, provided, however, that in no event shall GSK have the right
                                                                                                      to exploit any SpringWorks Background Patents to develop, manufacture or commercialize the SpringWorks Compound or a
                                                                                                      SpringWorks- Related Invention, either alone or as part of a combination (including the Combination Therapy). This license
                                                                                                      shall not be transferable or sublicensable to any Third Party except to Affiliates of GSK and Third Parties engaged in
                                                                                                      developing, manufacturing or marketing GSK Compound for or on behalf of its Affiliates.

 

		(b)	GSK hereby grants to SpringWorks a perpetual, irrevocable, non-exclusive, worldwide,
                                                                                                      royalty-free, fully paid-up license to (i) any patent owned or controlled by GSK which (A) has a priority claim that is
                                                                                                      earlier than the initiation of the Sub-Study (i.e., first dosing of the first patient in the Sub-Study) and (B) specifically
                                                                                                      claims or covers the Combination Therapy (“GSK Background Patents”) and (ii) [***] each in order to
                                                                                                      practice the Combination Therapy for all purposes, provided, however, that in no event shall SpringWorks have the right to
                                                                                                      exploit any GSK Background Patents to develop, manufacture or commercialize the GSK Compound or a GSK-Related Compound,
                                                                                                      either alone or as part of a combination (including the Combination Therapy). This license shall not be transferable or
                                                                                                      sublicensable to any Third Party except to Affiliates of SpringWorks and Third Parties engaged in developing,
                                                                                                      manufacturing or marketing SpringWorks Compound for or on behalf of its Affiliates.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 30 of 73

     

    

 

		(c)	Except as expressly provided in Section 16.4(c), and in furtherance and not in limitation of Article
13, each Party agrees to make no patent application based on or comprising the other Party’s Confidential Information and
to give no assistance to any Third Party for such application without the other Party’s prior written authorization.

 

		(d)	For clarity, the terms of this Agreement do not provide (i) GSK with any rights, title or interest
in or any license to the SpringWorks Background Intellectual Property except as necessary to conduct the Sub-Study or as expressly
provided under Section 16.5(a), and (ii) SpringWorks with any rights, title or interest in or any license to GSK Background Intellectual
Property except as expressly provided under Section 16.5(b).

 

		16.6	Reprints. Consistent with applicable copyright and other laws, each Party may use, refer
to, and disseminate reprints of scientific, medical and other published articles and materials from journals, conferences and/or
symposia relating to the Sub-Study which disclose the name of a Party, provided such use does not constitute an endorsement of
any commercial product or service by the other Party.

 

		17.	PUBLICATIONS.

 

		17.1	GSK will register the Sub-Study with the Clinical Trials Registry located at www.clinicaltrials.gov
and is committed to timely publication of the results following Sub-Study Completion, after taking appropriate action to secure
Intellectual Property Rights (if any, in accordance with Article 16) arising from the Sub-Study. The publication of the results
of the Sub-Study will be in accordance with the Sub-Study Protocol. [***].

 

		17.2	GSK shall use reasonable efforts to publish or present scientific papers dealing with the Sub-Study
in accordance with accepted scientific practice.

 

		17.3	The Parties agree that prior to submission of the results of the Sub-Study for publication or presentation
or any other dissemination of results including oral dissemination, the publishing Party shall invite the other to comment on the
content of the material to be published or presented according to the following procedure:

 

		(a)	At least [***] days prior to submission for publication of any paper, letter or any other publication,
or [***]days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party
shall provide to the other Party the full details of the proposed publication or presentation in electronic version (CD-ROMs or
email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation
for an additional [***] days in order to allow for actions to be taken to preserve rights for patent protection.

 

		(b)	The publishing Party shall give reasonable consideration to any request by the other Party made
within the periods mentioned in clause (a) above to modify the publication.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 31 of 73

     

    

 

		(c)	The publishing Party shall remove all Confidential Information requested by the other Party before
finalizing the publication.

 

		(d)	In the event of a disagreement as to content, timing and/or venue or forum for any disclosure,
publication or presentation of the Sub-Study results, such dispute shall be referred to the Project Managers (or their respective
designees) to be resolved by way of good faith discussions for a period of [***] days following such referral; provided that, the
publishing Party may proceed with the disclosure, publication or presentation provided that such disclosure, publication or presentation
is consistent with its internal publication guidelines and customary industry practices for the publication of similar data and
does not disclose the Confidential Information of the other Party (other than the Licensed Clinical Data). Authorship of any publication
shall be determined based on the accepted standards used in peer-reviewed academic journals at the time of the proposed disclosure,
publication or presentation.

 

		(e)	SpringWorks shall not publish, for any purpose, the results of the Sub-Study without the prior
written approval of GSK, which approval shall be obtained in accordance with the procedure set forth in Sections 17.3(a) through
17.3(c) and shall not be unreasonably withheld.

 

		17.4	SpringWorks may issue a press release in the form attached hereto as Appendix C provided, however,
that SpringWorks shall notify [***] Business Days in advance of such press release.

 

		17.5	Each Party agrees to identify the other Party and acknowledge the other Party’s support and
contributions in any permitted press release and any other permitted publication or presentation of the results of the Sub-Study.

 

		18.	USE OF NAME.

 

		18.1	Except as otherwise provided herein, neither Party shall have any right, express or implied, to
use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party
for any purpose in connection with the performance of this Agreement.

 

		19.	REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.

 

		19.1	Each of GSK and SpringWorks represents and warrants to the other that it has the power and authority
and the legal right to enter into this Agreement and perform its obligations hereunder.

 

		19.2	GSK hereby represents and warrants to SpringWorks that, at the time of Delivery of the GSK Compound,
such Compound shall have been Manufactured in compliance with: (a) the Specifications for the GSK Compound; and (b) all Applicable
Law, including cGMP and health, safety and environmental protections.

 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 32 of 73

     

    

 

		19.3	SpringWorks hereby represents and warrants to GSK that, at the time of Delivery of the SpringWorks
Compound, such SpringWorks Compound shall have been Manufactured in compliance with: (a) the Specifications for the SpringWorks
Compound; (b) the Clinical Quality Agreement; and (c) all Applicable Law, including cGMP and health, safety and environmental protections.

 

		19.4	Each Party represents and warrants to the other Party that, to its knowledge, it is not aware of
any pending or threatened litigation (and has not received any communication) that alleges that its activities related to this
Agreement have violated, or that by conducting the activities as contemplated in this Agreement it would violate, any of the Intellectual
Property Rights of any Third Party (after giving effect to the license grants in this Agreement).

 

		19.5	Each Party represents and warrants to the other Party that, to its knowledge, all necessary consents,
approvals and authorizations of all regulatory and governmental authorities and other persons required to be obtained by such Party
in connection with the performance of its obligations under this Agreement have been obtained or will be obtained prior to such
performance.

 

		19.6	Each Party represents and warrants to the other Party that it shall comply with all Applicable
Law of the country or other jurisdiction, or any court or agency thereof, applicable to the performance of its activities hereunder
or any obligation hereunder, including those pertaining to the production and handling of therapeutic drug products, such as those
set forth by Regulatory Authorities, as applicable, and the applicable terms of this Agreement in the performance of its obligations
hereunder.

 

		19.7	Each Party shall comply with its respective obligations under any agreements entered into by it
with a Third Party under which it is licensed any Intellectual Property Rights or Confidential Information relating to a Compound
(and not to voluntarily terminate same) to the extent necessary for the Sub-Study to be conducted and completed in accordance with
the terms of this Agreement and for the other Party to receive the rights and benefits provided to it under this Agreement.

 

		19.8	GSK DOES NOT UNDERTAKE THAT THE SUB-STUDY SHALL LEAD TO ANY PARTICULAR RESULT, NOR IS THE SUCCESS
OF THE SUB-STUDY GUARANTEED. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY USE THAT THE OTHER PARTY MAY MAKE OF THE LICENSED
CLINICAL DATA NOR FOR ADVICE OR INFORMATION GIVEN IN CONNECTION THEREWITH.

 

		19.9	EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE 19, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL
PROPERTY RIGHTS, WITH RESPECT TO ITS COMPOUND.

 

    	Page 33 of 73

     

    

 

		19.10	Each Party hereby represents and warrants that it has not employed or otherwise used in any capacity
and will not employ or otherwise use in any capacity, the services of any person that has been Debarred in performing any portion
of the Sub-Study or other activities under this Agreement or the Related Agreements and that this warranty may be relied upon in
any applications to a Regulatory Authority. It is understood and agreed that this warranty imposes a continuing obligation on each
Party to notify the other in writing immediately if any such Debarment occurs or comes to its attention, and each Party shall,
with respect to any person so Debarred, promptly remove such person from performing in any capacity related to the Sub-Study or
otherwise related to activities under this Agreement or the Related Agreements.

 

		20.	ANTI-CORRUPTION

 

		20.1	Each Party agrees that it:

 

		(a)	shall comply at all times with Applicable Law;

 

		(b)	has not, and covenants that it shall not, in connection with the performance of this Agreement,
directly or indirectly make, promise, authorize, ratify or offer to make, or request, receive, or agree to receive or take any
act in furtherance of, any payment or transfer of anything of value (i) for the purpose of influencing, inducing or rewarding any
act, omission or decision to secure an improper advantage; (ii) for the purpose of improperly assisting it in obtaining or retaining
business; or (iii) with the purpose or effect of committing an act of bribery; and

 

		(c)	warrants that it has taken reasonable measures to prevent subcontractors, agents or any other Third
Parties subject to its control or determining influence from committing any of the acts described in Section 20.1(b), and for the
avoidance of doubt, the activities described above shall include facilitating payments which are unofficial or improper and small
payments or gifts offered or made to Government Officials to secure or expedite a routine or necessary action.

 

		20.2	Except as required by Applicable Law, or in the ordinary course of business, including audits and
inspections of SpringWorks facilities by Regulatory Authorities, SpringWorks shall not contact, or otherwise knowingly meet with
any Government Official for the purpose of discussing activities arising out of or in connection with this Agreement, without the
prior written approval of GSK and, when requested by GSK, only in the presence of a GSK designated representative.

 

		20.3	SpringWorks shall inform GSK in writing, if, during the course of this Agreement, it is convicted
of or pleads guilty to a criminal offence involving fraud or corruption, or becomes the subject of any government investigation
for such offenses, or is listed by any government agency as debarred, suspended, proposed for suspension or debarment, or otherwise
ineligible for government programs.

 

    	Page 34 of 73

     

    

 

		20.4	SpringWorks represents and warrants that except as disclosed to GSK in writing prior to the commencement
of this Agreement: (a) to its knowledge, none of their significant shareholders (>25% shareholding) or senior management have
influence over GSK’s business; (b) to its knowledge, no significant shareholders (>25% shareholding), members of senior
management team, members of the Board of Directors, or key individuals who will be responsible for the provision of goods / services,
are currently or have been in the past two years a Government Official with actual or perceived influence which could affect GSK
business; (c) it is not aware of any immediate relatives (e.g. spouse, parents, children or siblings) of the persons listed in
the previous subsection (b) having a public or private role which involves making decisions which could affect GSK business or
providing services or products to, or on behalf of GSK; (d) it does not have any other interest which directly or indirectly conflicts
with its proper and ethical performance of this Agreement; and (e) it shall maintain arm’s length relations with all third
parties with which it deals for or on behalf of GSK in performance of this Agreement. SpringWorks shall inform GSK in writing at
the earliest possible opportunity of any conflict of interest as described in this Section 20.4 that arises during the performance
of this Agreement.

 

		20.5	GSK shall have the right once per calendar year during the term of this Agreement to conduct an
audit of SpringWorks’ books and records related to this Agreement solely as and to the extent reasonably required to monitor
compliance with the terms of Article 20, provided that GSK shall be permitted to conduct more frequent audits to the extent GSK
reasonably believes that SpringWorks is not complying with the terms of this Article 20 and further provided that such audits shall
be conducted during normal business without unreasonable disruption to SpringWorks business. SpringWorks shall reasonably cooperate
with such audit. The audit shall be conducted by an independent professional firm proposed by GSK and acceptable to SpringWorks.
Before permitting such firm to have access to SpringWorks’ books and records, SpringWorks may require such firm and its personnel
involved in such audit to sign a confidentiality agreement (save that such agreement will not prohibit transmission of information
to GSK).

 

		20.6	SpringWorks shall ensure that all transactions under the Agreement are properly and accurately
recorded in all material respects on its books and records and each document upon which entries such books and records are based
is complete and accurate in all material respects. SpringWorks must maintain a system of internal accounting controls reasonably
designed to ensure that it maintains no off-the-books accounts.

 

		20.7	SpringWorks agrees that in the event that GSK believes that there has been a possible violation
of this Article 20, GSK may make full disclosure of such belief and related information at any time and for any reason to any competent
government bodies and its agencies, and to whomsoever GSK determines in good faith has a legitimate need to know.

 

		20.8	SpringWorks shall provide anti-bribery and anti-corruption training to all personnel, including
any relevant subcontractors, at SpringWorks who act on behalf of GSK or interact with Government Officials during the course of
any services provided to GSK in connection with this Agreement. SpringWorks shall provide GSK the opportunity to evaluate the training
to determine whether it abides by GSK’s standards and shall conduct additional training, as requested by GSK. SpringWorks,
upon request by GSK, shall certify in writing that the anti-bribery and anti-corruption training has taken place.

 

		20.9	Each Party shall be entitled to terminate this Agreement immediately on written notice to the other
Party if such other Party is in breach of this Article 20. The breaching Party shall have no claim against the non-breaching Party
for compensation for any loss of whatever nature by virtue of the termination of this Agreement in accordance with this Section
20.9.

 

    	Page 35 of 73

     

    

 

		21.	INSURANCE.

 

		21.1	Each Party warrants that it maintains a policy or program of insurance or self-insurance of at
least $5,000,000 per claim and $5,000,000 in the aggregate. Upon request, a Party shall provide evidence of such insurance. The
maintenance of any insurance shall not constitute any limit or restriction on damages available to a Party under this Agreement.

 

		22.	INDEMNIFICATION.

 

		22.1	Indemnification by GSK. GSK agrees to defend, indemnify and hold harmless SpringWorks, its
Affiliates, and its and their employees, directors, subcontractors and agents from and against any loss, damage, reasonable costs
and expense (including reasonable legal expenses, including attorneys’ fees and expenses) incurred in connection with any
claim, proceeding, or action by a Third Party (a “Liability”) arising out of this Agreement or the Sub-Study
to the extent such Liability (a) is directly caused by (i) the negligence or wilful misconduct on the part of GSK (or any of its
Affiliates, or its and their employees, directors, subcontractors or agents); or (ii) a breach on the part of GSK of any of its
representations and warranties or any other covenants or obligations of GSK under this Agreement; or (b) is determined to be attributable
to the GSK Compound.

 

		22.2	Indemnification by SpringWorks. SpringWorks agrees to defend, indemnify and hold harmless
GSK, its Affiliates, and its and their employees, directors, subcontractors and agents from and against any Liability arising out
of this Agreement or the Sub-Study to the extent such Liability (a) is directly caused by (i) the negligence or wilful misconduct
on the part of SpringWorks (or any of its Affiliates, or its and their employees, directors, subcontractors or agents); or (ii)
a breach on the part of SpringWorks of any of its representations and warranties or any other covenants or obligations of SpringWorks
under this Agreement; or (b) is determined to be attributable to the SpringWorks Compound.

 

		22.3	Procedure. The obligations of GSK and SpringWorks under this Article 22 are conditioned
upon the delivery of written notice to the relevant indemnifying Party of any potential Liability within a reasonable time after
the indemnified Party becomes aware of such potential Liability. The indemnifying Party will have the right to assume the defense
of any suit or claim related to the Liability if it has assumed responsibility for the suit or claim in writing and the indemnified
Party shall provide reasonable assistance to the indemnifying Party, at the indemnifying Party’s expense, in the investigation
of, preparation for and defense of any such suit or claim. The indemnified Party may participate in (but not control) the defense
thereof at its sole cost and expense. The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof. The Party controlling the defense shall not agree to any settlement
of such action, suit, proceeding or claim without the prior written consent of the other Party, which shall not be unreasonably
withheld. The controlling Party, but solely to the extent it is also the indemnifying Party, shall not agree to any settlement
of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional
release of the non-controlling Party from all liability with respect thereto or that imposes any liability or obligation on the
non-controlling Party without the prior written consent of the non-controlling Party.

 

    	Page 36 of 73

     

    

 

		22.4	Notwithstanding the provisions of Section 22.3, in the event that the Parties cannot agree as to
the application of Sections 22.1 or 22.2 regarding any particular Liability, the Parties may conduct separate defenses of any suit
or claim related to such Liability. Each Party further reserves the right to claim indemnity from the other in accordance with
Sections 22.1 or 22.2, as applicable, upon resolution of the underlying claim.

 

		22.5	Sub-Study Subjects. GSK shall not offer compensation on behalf of SpringWorks to any Sub-Study
subject or bind SpringWorks to any indemnification obligations in favor of any Sub-Study subject.

 

		23.	LIMITATION OF LIABILITY

 

		23.1	OTHER THAN WITH RESPECT TO THE OBLIGATIONS OF EITHER PARTY UNDER SECTIONS 4 (EXCLUSIVITY) AND 16.4(B)
(INTELLECTUAL PROPERTY) AND ARTICLES 13 (CONFIDENTIALITY) AND 14 (DATA PROTECTION) AND/OR A PARTY’S INDEMNIFICATION OBLIGATIONS
HEREUNDER: (A) IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES, SUBLICENSEES OR SUBCONTRACTORS) BE LIABLE TO THE OTHER
PARTY FOR ANY INDIRECT, PUNITIVE OR CONSEQUENTIAL OR SPECIAL DAMAGES (INCLUDING LOST PROFITS OR DAMAGES FOR LOST OPPORTUNITIES),
WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR RELATING TO (x) THE MANUFACTURE,
USE OR SALE OF ANY COMPOUND SUPPLIED HEREUNDER OR (y) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT
OR ANY REPRESENTATION OR WARRANTY CONTAINED IN OR MADE PURSUANT TO THIS AGREEMENT; AND [***]. NOTWITHSTANDING ANYTHING TO THE CONTRARY
IN THIS AGREEMENT, NEITHER PARTY EXCLUDES OR LIMITS ITS LIABILITY FOR FRAUD, DEATH OR PERSONAL INJURY CAUSED BY ITS NEGLIGENCE
OR THAT OF ITS AFFILIATES, AND ITS AND THEIR EMPLOYEES, DIRECTORS, SUBCONTRACTORS AND AGENTS, WILFUL MISCONDUCT, INTENTIONAL DEFAULT
OR ANY LOSSES TO THE EXTENT NOT CAPABLE OF BEING EXCLUDED OR LIMITED BY LAW.

 

		24.	TERM AND TERMINATION.

 

		24.1	The term of this Agreement shall commence on the Effective Date and shall continue in full force
and effect until Sub-Study Completion, delivery of all Licensed Clinical Data and the Final Sub-Study Report, and the completion
of any analyses contemplated by the Sub-Study Protocol or otherwise agreed by the Parties to be conducted under this Agreement,
unless earlier terminated by either Party pursuant to this Article 24 (the “Term”).

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 37 of 73

     

    

 

		24.2	Either Party may immediately terminate this Agreement on notice if the other Party commits a material
breach of this Agreement, and such material breach is either not capable of cure or is not cured within [***] days after receipt
of written notice thereof from the non-breaching Party.

 

		24.3	Either Party may terminate this Agreement if, at any time, the other Party shall file in any court
or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of such other Party’s
assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall
be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed
or stayed within [***] days after the filing thereof, or if the other Party will propose or be a party to any dissolution or liquidation,
or if the other Party shall make an assignment for the benefit of its creditors.

 

		24.4	Termination due to Regulatory Action, Material Safety Issue or Clinical Hold.

 

		(a)	Either Party may terminate this Agreement (in whole or in part on a country-by-country basis) immediately
upon written notice to the other Party in the event that any Regulatory Authority takes any action, or raises any objection, that
prevents the terminating Party from supplying its Compound for purposes of the Sub-Study. Additionally,
either Party shall have the right to terminate this Agreement immediately (in whole or in part) upon written notice to the other
Party in the event that it determines in its sole discretion to discontinue development, marketing or sale of its Compound for
medical, scientific or legal reasons.

 

		(b)	Either Party may terminate this Agreement (in whole or in part on a country-by-country basis) immediately
(after meeting and discussing with the other Party in good faith) upon written notice to the other Party if the terminating Party
determines in good faith, based on a review of the Licensed Clinical Data or the Clinical Data, as applicable, or other available
information, that termination is necessary to protect the safety, health or welfare of subjects enrolled in the Sub-Study due to
the existence of a Material Safety Issue. In the event of a termination due to a Material Safety Issue, prior to provision of notice
by the terminating Party, the Parties shall, to the extent practicable, meet and discuss in good faith the safety concerns raised
by the terminating Party, but should any dispute arise in such discussion, the dispute resolution processes set forth in Article
30 shall not apply and the terminating Party shall have the right to issue such notice and such termination shall take effect.

 

		(c)	If a Clinical Hold with respect to either the GSK Compound or the SpringWorks Compound should arise
at any time during the Term, the Parties will meet and discuss the basis for the Clinical Hold, how long the Clinical Hold is expected
to last, and how the issue that caused the Clinical Hold might be addressed. If, after ninety (90) days of discussions following
the Clinical Hold, either Party reasonably concludes that the issue adversely impacts the Sub-Study and is not solvable or that
unacceptable and material additional costs/delays have been and/or will continue to be incurred in the conduct of the Sub-Study,
then such Party may immediately terminate this Agreement.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 38 of 73

     

    

 

		25.	EFFECT OF EXPIRY OR TERMINATION.

 

		25.1	The provisions of Sections 7.2 (Right of Reference) and 12.16 (VAT) and Articles 1 (Definitions),
3 (Costs of Sub-Study), 5 (Follow On Studies), 13 (Confidentiality), 14 (Data Protection), 15 (Clinical Data Ownership & Use),
16 (Intellectual Property), 17 (Publications), 18 (Use of Name), 19 (Representations and Warranties; Disclaimers), 22 (Indemnification),
23 (Limitation of Liability), 25 (Effect of Expiry or Termination), 26 (Force Majeure), 27 (Entire Agreement; Modification), 28
(Assignment), 29 (Severability), 30 (Governing Law and Dispute Resolution and Jurisdiction), 31 (Notices), 32 (No Waiver), 33 (Further
Assurances), 34 (No Benefit to Third Parties) 35 (Relationship of the Parties) and 37 (Construction) shall survive the expiration
or termination of this Agreement.

 

		25.2	Termination or expiration of this Agreement shall be without prejudice to any claim or right of
action of either Party against the other Party for any prior breach of this Agreement.

 

		25.3	Upon termination or expiration of this Agreement:

 

		(a)	GSK shall, at SpringWorks’ sole discretion, promptly either return or destroy all unused
SpringWorks Compound pursuant to SpringWorks’ instructions, subject to GSK’s rights under Section 25.3(c). If SpringWorks
requests that GSK destroy the unused SpringWorks Compound, GSK shall provide written certification of such destruction and written
notification of the quantity of SpringWorks Compound thus destroyed;

 

		(b)	the receiving Party shall, upon request by the other Party, immediately destroy or return all of
the other Party’s Confidential Information relating solely to its Compound (but not to the Combination Therapy or the GSK
Compound) in its possession; provided that the receiving Party shall be entitled to retain one (1) copy of such Confidential Information
solely for record-keeping purposes and shall not be required to destroy any Confidential Information required, or reasonably necessary,
to be retained for any clinical trial activities that continue after expiration or termination of this Agreement, or off-site computer
files created during automatic system back-up which are subsequently securely stored by the receiving Party;

 

		(c)	the Parties shall use reasonable efforts to wind down activities under this Agreement in a reasonable
manner and avoid incurring any additional expenditures or non-cancellable obligations, provided that (i) in the event of termination
under Section 24.4, the Parties shall work together in good faith to ensure that each Party is able to comply with any ongoing
regulatory or other obligations (including regulatory reporting obligations, clinical site and investigator communications) under
Applicable Law relating to its Compound or the Combination Therapy, as the case may be, and (ii) GSK may continue to dose subjects
enrolled in the Sub-Study through completion of the Sub-Study Protocol if dosing is required by the applicable Regulatory Authority(ies),
ethical approvals, the Platform Study Protocol, Applicable Law and/or GSK’s internal policies, in which case SpringWorks
shall continue to supply SpringWorks Compound in accordance with Article 12 until such dosing is complete.

 

    	Page 39 of 73

     

    

 

		26.	FORCE MAJEURE.

 

		26.1	If in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by
reason of any cause beyond such Party’s reasonable control (e.g., war, riots, fire, strike, governmental laws), such Party
shall be excused from such performance to the extent that it is necessarily prevented, hindered or delayed (“Force Majeure”).
The non-performing Party will use reasonable efforts to notify the other Party of such Force Majeure within [***] after such occurrence
by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken
to avoid or minimize its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary
and the non-performing Party will use commercially reasonable efforts to remedy its inability to perform. If the period of any
resulting delay or hindrance to such Party’s performance of its obligations, or non-performance thereof, continues for [***],
the other Party may terminate this Agreement immediately upon written notice to the non-performing Party.

 

		27.	ENTIRE AGREEMENT; MODIFICATION.

 

		27.1	This Agreement, together with the Clinical Quality Agreement and the Pharmacovigilance Agreement,
constitutes the sole, full, final, complete and exclusive agreement by and between the Parties with respect to the subject matter
of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect
thereto are superseded by this Agreement. No amendments, changes, additions, deletions or modifications to or of this Agreement
shall be valid unless reduced to writing and duly executed by authorized representatives of the Parties hereto.

 

		28.	ASSIGNMENT.

 

		28.1	Neither Party shall assign or transfer its rights or obligations under this Agreement in part or
in whole without the prior written consent of the other Party; provided, however, that (a) either Party may assign this Agreement,
without the other Party’s consent, to (i) one or more of its Affiliates, (ii) a Third Party that merges with, consolidates
with or acquires substantially all of the assets or voting control of the assigning Party or (iii) to a Third Party that acquires
all the rights of the assigning Party to the GSK Compound, in the case of GSK, or the SpringWorks Compound, in the case of SpringWorks;
and (b) any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided that such
Affiliates agree to be bound by this Agreement. If this Agreement is assigned or transferred to an Affiliate, the assigning/transferring
Party shall remain jointly and severally liable with the assignee/transferee Affiliate for the assigned rights and obligations.
Any assignment or attempted assignment by any Party in violation of the terms of this Article 28 shall be null and void and of
no legal effect.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 40 of 73

     

    

 

		29.	SEVERABILITY.

 

		29.1	If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining
provisions shall remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision. The
illegal, invalid or unenforceable provision (or such part of such provision) shall be severed from this Agreement, and the Parties
shall negotiate in good faith to agree upon a reasonable provision that is legal, valid and enforceable to carry out as nearly
as practicable the original intention of the entire Agreement.

 

		30.	GOVERNING LAW, DISPUTE RESOLUTION AND JURISDICTION.

 

		30.1	Governing Law. This Agreement shall be governed and construed in accordance with the substantive
laws of the State of New York, without giving effect to its choice of law principles.

 

		30.2	Dispute Resolution and Jurisdiction.

 

		(a)	Subject to the other terms of this Agreement, the Parties agree that any dispute arising out of
or relating to this Agreement (each, a “Dispute”) shall be resolved solely by means of the procedures set forth
in this Section 30.2 prior to a Party exercising any other remedy permitted by this Agreement (other than seeking injunctive relief),
and that such procedures constitute legally binding obligations that are an essential provision of this Agreement. If either Party
fails to observe the procedures of this Section 30.2, the other Party may bring an action for specific performance of these procedures
in any court of competent jurisdiction.

 

		(b)	Negotiation. The Parties shall endeavor to resolve in good faith any Disputes arising from or relating
to the subject matter of this Agreement, failing which either Party may submit such Dispute for resolution to appropriate senior
management of SpringWorks and GSK. If such senior management representatives are unable to resolve such Dispute within [***] days
after such conflict is submitted to them for resolution, either Party may refer the Dispute for mediation as set forth in Section
30.2(c).

 

		(c)	Mediation. If the Parties are unable to resolve a Dispute arising out of or relating to this Agreement
through the negotiation procedures set forth in Section 30.2(b), then at the end of such [***] day period, the Parties agree that
they shall submit such Dispute for confidential mediation under the CPR Mediation Procedure then in effect at the start of mediation
(the “CPR”). Unless otherwise agreed, the Parties shall select a mediator from the CPR panel of mediators. If
the Parties cannot agree, they will defer to the CPR to select a mediator. The cost of the mediator shall be borne equally by the
Parties. Any Dispute not resolved within [***] days (or within such other time period as may be agreed to by the Parties in writing)
after appointment of a mediator shall be finally resolved by arbitration pursuant to Section 30.2(b).

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Page 41 of 73

     

    

 

		(d)	Arbitration. If the Parties are unable to resolve a Dispute arising out of or relating to this
Agreement through the negotiation procedures set forth in Section 30.2(b) and the mediation procedures set forth in Section 30.2(c)
within the timeframes set forth in such Sections, the Parties agree that they shall submit such Dispute for final settlement via
binding arbitration. The arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association
in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the Parties, but need
not be under the auspices of the American Arbitration Association, and heard before a single arbitrator as selected in accordance
with the Commercial Arbitration Rules. Such arbitration will be held in New York, New York and shall be conducted in English. Each
Party shall be responsible for its own expenses in connection therewith; provided that, upon the rendering of the arbitration award,
the non-prevailing party shall reimburse the prevailing Party for the arbitration fees. The Parties hereby submit to the nonexclusive
jurisdiction of the United States District Court for the Southern District of New York for the limited purpose of enforcing this
Agreement to arbitrate. The arbitration award shall be final and binding, and judgment over the award may be entered by any court
having jurisdiction thereof or having jurisdiction over the relevant Party and its assets.

 

		(e)	Confidentiality. The arbitration proceeding shall be confidential and the arbitrators shall issue
appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by Applicable Law, no
Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the
arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and any award
shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award
or as otherwise required by Applicable Law. Notwithstanding the foregoing, each Party shall have the right to disclose information
regarding the arbitration proceeding to the same extent as it may disclose Confidential Information of the other Party under Article
13 above.

 

		(f)	Patent Disputes. Notwithstanding the other provisions of this Section 30.2, any dispute, controversy
or claim relating to the validity, scope, enforceability, inventorship, or ownership of intellectual property rights shall be submitted
to a court of competent jurisdiction in the country in which such intellectual property rights were granted or arose.

 

		30.3	Injunctive or Other Equitable Relief. Nothing contained in this Agreement shall deny either
Party the right to seek injunctive or other equitable relief or interim or provisional relief from any court of competent jurisdiction,
including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either
prior to or during any arbitration if necessary in order to prevent irreparable harm, loss or damage, protect the interests of
such Party or to preserve the status quo pending the arbitration proceeding, and such an action may be filed or maintained notwithstanding
any ongoing discussions between the Parties. For the avoidance of doubt, the other Party shall have the right to seek injunctive
or other equitable relief precluding the other Party from continuing its activities related to the Sub-Study without waiting for
the conclusion of the dispute resolution procedures set out in this Article 30 if (a) either Party (i) discloses Confidential Information
of the other Party other than as permitted under this Agreement, (ii) uses the other Party’s Compound or Intellectual Property
Rights in any manner other than as expressly permitted by this Agreement, or (iii) otherwise is in material breach of this Agreement
and such material breach could cause immediate harm to the value of the GSK Compound (if SpringWorks is in material breach) or
the SpringWorks Compound (if GSK is in material breach), or (b) if SpringWorks is in breach of Section 4.1.

 

    	Page 42 of 73

     

    

 

		31.	NOTICES.

 

		31.1	All notices or other communications that are required or permitted hereunder shall be in writing
and delivered by internationally-recognized overnight courier addressed as follows:

 

If to GSK, to:

 

GlaxoSmithKline

1250 South Collegeville Road, Mail Stop UP 4110

Collegeville, PA 19426

Attn: Head of Business Development, Oncology

 

With a copy to

 

GlaxoSmithKline

980 Great West Road

Brentford, Middlesex TW8 9GS

United Kingdom

Attn: VP and Head of Legal Business Development & Corporate

 

If to SpringWorks, to:

 

SpringWorks Therapeutics

100 Washington Blvd. 5th Floor

Stamford, CT 06902

Attention: Chief Business Officer

 

With copies to:

 

SpringWorks Therapeutics

100 Washington Blvd. 5th Floor

Stamford, CT 06902

Attention: General Counsel

 

Any such communication shall
be deemed to have been received when delivered to the recipient, if sent before 5.00 pm on a Business Day in the recipient’s
jurisdiction, or at 09.00 am on the next Business Day in the recipient’s jurisdiction, if sent after 5.00 pm or not on a
Business Day. It is understood and agreed that this Article 31 is not intended to govern the day-to-day business communications
necessary between the Parties in performing their duties, in due course, under the terms of this Agreement.

 

    	Page 43 of 73

     

    

 

		32.	NO WAIVER.

 

		32.1	It is agreed that no waiver by a Party of any breach or default of any of the covenants or agreements
set forth herein shall be deemed a waiver as to any subsequent and/or similar breach or default.

 

		33.	FURTHER ASSURANCE.

 

		33.1	Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further
instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents
and instruments, as may be necessary or as the other Party may reasonably request in order to perfect any license, assignment or
other transfer or any properties or rights under, or pursuant, to this Agreement.

 

		34.	NO BENEFIT TO THIRD PARTIES.

 

		34.1	The representations, warranties and agreements set forth in this Agreement for the sole benefit
of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other
Parties.

 

		35.	RELATIONSHIP OF THE PARTIES.

 

		35.1	The relationship between the Parties is and shall be that of independent contractors, and does
not and shall not constitute a partnership, joint venture, agency or fiduciary relationship. Neither Party shall have the authority
to make any statements, representations or commitments of any kind, or take any actions, for or on behalf of the other Party, except
with the prior written consent of the other Party to do so. All persons employed by a Party will be the employees of such Party
and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and
expense of such Party.

 

		36.	COUNTERPARTS AND DUE EXECUTION.

 

		36.1	This Agreement and any amendment may be executed in two (2) or more counterparts (including by
way of electronic transmission (e.g. PDF)), each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from
computers or printers and such signatures shall be deemed to bind each Party hereto as if they were original signatures. When executed
by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage and
printing of copies of this Agreement from computers or printers. For clarity, signatures transmitted via PDF shall be treated as
original signatures.

 

    	Page 44 of 73

     

    

 

		37.	CONSTRUCTION.

 

		37.1	Except where the context otherwise requires, wherever used, the singular will include the plural,
the plural the singular, the use of any gender will be applicable to all genders, the word “or” is used in the inclusive
sense (and/or), and the words “will” and “shall” are synonymous to indicate an obligation. Whenever this
Agreement refers to a particular statute or regulation, such reference shall include all rules and regulations promulgated thereunder
and any successor statute, rules or regulations then in effect, in each case including the then-current amendments thereto. Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this
Agreement are for convenience of reference only and in no way, define, describe, extend or limit the scope or intent of this Agreement
or the intent of any provision contained in this Agreement. The term “including” as used herein shall be deemed to
be followed by the phrase “without limitation” or like expression. The term “will” as used herein means
shall. References to “Article,” “Section” or “Appendix” are references to the numbered sections
of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise. Except where the context otherwise
requires, references to this “Agreement” shall include the appendices attached to this Agreement. The language of this
Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied
against either Party hereto.

 

[Signature page follows.]

 

    	Page 45 of 73

     

    

 

IN WITNESS WHEREOF,
the respective representatives of the Parties have executed this Agreement as of the Effective Date.

 

	GLAXOSMITHKLINE LLC	 
	 	 
	/s/ John Cantello	 
	Signature	 
	 	 
	John Cantello	 
	Name	 
	 	 
	VP Business Development	 
	Title	 

 

[SIGNATURE PAGE TO CTCSA]

 

     

     

    

 

SPRINGWORKS THERAPEUTICS, INC.

 

	/s/ Saqib Islam	 
	Signature	 
	 	 
	Saqib Islam	 
	Name	 
	 	 
	Chief Executive Officer	 
	Title	 
	 	 
	June 25, 2019	 
	Date	 

 

[SIGNATURE PAGE TO CTCSA]

 

     

     

    

 

Appendix A

 

SUB-STUDY PROTOCOL SUMMARY

 

Appendix A

[***] 

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

  

    	

     

    

 

Appendix B

 

SUPPLY OF COMPOUND

 

Schedule of Deliveries for SpringWorks
Compound

 

	Delivery Date	Quantity of Bottles1
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	Total	[***]

 

	Delivery Date2	Quantity of Bottles
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

 

 

1
[***].

 

2
Delivery Dates for, and Quantities of, SpringWorks Compound are estimates only. Delivery Dates and Quantities may change based
on Sub-Study requirements and as agreed by the Parties in accordance with this Agreement.

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

 

    	Appendix B

     

    

 

Schedule I

 

[***]

 

[***]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed.

 

    	Appendix C

     

    

 

Appendix C

 

PRESS RELEASE

 

SpringWorks Therapeutics Announces Global
Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with
Relapsed or Refractory Multiple Myeloma

 

STAMFORD, Conn - June XX, 2019 -
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients
with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaboration agreement
with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat,
in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC),
belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.

 

Gamma secretase is an enzyme that cleaves
multiple transmembrane proteins, including BCMA. As evidenced in publications and preclinical experiments, treatment with a GSI,
including nirogacestat, can increase BCMA cell surface expression levels on multiple myeloma cells1, potentially improving
the activity of BCMA-targeted therapies, including BCMA ADCs.

 

“While significant advances have
been made in treating multiple myeloma over the past decade, a significant unmet need remains for patients who have relapsed or
are refractory to available treatments,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics. “We
are delighted to enter into this agreement with GlaxoSmithKline, who also invested in our recent Series B financing, and we look
forward to exploring the potential benefit of nirogacestat and belantamab mafodotin for multiple myeloma patients. With this collaboration,
we are pleased to further expand on our strategy in building our targeted oncology portfolio with another industry leader.”

 

Under the terms of the agreement, GlaxoSmithKline
will sponsor and conduct the adaptive Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combination,
and will assume all development costs associated with the study. GlaxoSmithKline and SpringWorks Therapeutics will also form a
joint development committee to manage the clinical study.

 

About Nirogacestat

 

Nirogacestat is an investigational, oral,
selective, small molecule gamma-secretase inhibitor in Phase 3 clinical development for desmoid tumors, which are rare and often
debilitating and disfiguring soft-tissue tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch,
which is believed to play a role in activating pathways that contribute to desmoid tumor growth. In June 2018, the FDA granted
Orphan Drug designation for nirogacestat for the treatment of desmoid tumors, and in November 2018, the FDA granted Fast Track
designation for nirogacestat for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid
tumors or deep fibromatosis.

 

    	Appendix C

     

    

 

In addition, gamma secretase has been shown
to directly cleave membrane-bound BCMA, resulting in the release of the BCMA extracellular domain, or ECD, from the cell surface.
By inhibiting gamma secretase, membrane-bound BCMA can be preserved, increasing target density while reducing levels of soluble
BCMA ECD, which may serve as decoy receptors for BCMA- directed therapies.2 Nirogacestat’s ability to enhance
the activity of BCMA-directed therapies has been observed in preclinical models of multiple myeloma.

 

About belantamab mafodotin (GSK2857916)

 

Belantamab mafodotin is an investigational
anti-B-cell maturation antigen (BCMA) antibody-drug conjugate in Phase 2 clinical development for patients with relapsed/refractory
multiple myeloma and other advanced hematologic malignancies expressing BCMA.

 

In 2017, belantamab mafodotin was awarded
Breakthrough Therapy designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency;
these designations are intended to facilitate development of investigational medicines that have shown clinical promise for conditions
where there is significant unmet need.

 

About SpringWorks Therapeutics

 

At SpringWorks Therapeutics, a clinical-stage
biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer.
Since our launch in 2017, we have worked to identify and advance promising science, beginning with our licensed clinical therapies
from Pfizer Inc. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy
groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new
therapies to underserved patients. Nirogacestat, our gamma secretase inhibitor for the treatment of desmoid tumors is currently
in a Phase 3 clinical trial, and SpringWorks Therapeutics expects to initiate a Phase 2b study of PD-0325901, our MEK 1/2 inhibitor
for neurofibromatosis type 1 patients with plexiform neurofibromas, in the third quarter of 2019. PD-0325901 also holds promise
as the backbone for combination therapies to treat metastatic solid tumors. At SpringWorks, we ignite the power of promising science
to unleash new possibilities for patients. For more information, please visit www.springworkstx.com.

 

Follow SpringWorks Therapeutics on social
media: @SpringWorksTx and LinkedIn.

 

References

 

1 Laurent S, Hoffmann F, Kuhn
P, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck S, Schuh E, Krumbholz M, Rubsamen H, Wanngren J, Khademi M, Olsson T, Alexander T,
Hiepe F, Pfister H, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler S, & Meinl E, Gamma-secretase directly sheds the
survival receptor BCMA from plasma cells, Nature Communications (2015).

 

2 Chen H, Li M, Xu N, Ng N,
Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg
R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR, Serum B- cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody
to multiple myeloma cells, Leukemia Research (2019), https://doi.org/10.1016/j.leukres.2019.04.008

 

Contact:

Kim Diamond

Vice President, Communications and Investor Relations

Phone: 646-661-1255

Email: kdiamond@springworkstx.com

 

    	Appendix C

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]